Role of Stathmin-1 in Colorectal Cancer Metastasis and Chemo-resistance by WU WEI





ROLE OF STATHMIN-1 IN COLORECTAL CANCER 











A THESIS SUBMITTED 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
DEPARTMENT OF BIOCHEMISTRY 
NATIONAL UNIVERSITY OF SINGAPORE 
2014 








I hereby declare that this thesis is my original  
work and it has been written by me in its entirety.  
I have duly acknowledged all the sources of  
information which have been used in the thesis. 
 
This thesis has also not been submitted for any  







23rd January 2014 
  






“All that is valuable in human society depends upon the 
opportunity for development accorded the individual.” 
-------- Albert Einstein. 
 
 
It was my utmost privilege to receive the mentorship of three great scientists. As I 
reflect in the final lap upon this journey, these opportunities appear even more 
valuable than ever. 
I am immensely grateful for the opportunity to work under A/P Maxey Chung Ching 
Ming, who saw faith in an enthusiastic but otherwise mediocre student. Without his 
encouragement and dedicated care, this amazing four-year adventure would never 
have been any more than the desire to explore. I also thank Dr. David Balasundaram 
for captivating me with his passion for science almost a decade ago. Till this day, I 
remember the shine in his eyes at that eureka moment we shared. I am also 
indebted to A/P Alan G Porter who provided the best environment to learn 
experimental techniques, and for trusting that a third-year undergraduate just picking 
up cancer biology was worth his time.  
I am also blessed to have supportive thesis advisors who were genuinely concerned, 
as well as efficient department staff whom I trouble frequently, but still remain 
friendly. This voyage was never lonely, for I had labmates who shared the joy of 
making discoveries and never failed to spur me on. Thank you all. 
This thesis is dedicated to my parents, who held the conviction that I was meant to 
pursue this path, and bestowed upon me the fortitude to take on this challenge. With 
your love, I made it. 
  iii   
 
  
Table of Contents 
 
 
Acknowledgement ....................................................................................................... ii 
List of figures ............................................................................................................. vii 
List of Tables .............................................................................................................. x 
Summary ................................................................................................................... xii 
Abbreviations ............................................................................................................ xiii 
 
 
Chapter 1 Introduction ............................................................................................. 1 
1.1 Colon cancer ................................................................................................ 2 
1.1.1 Colorectal carcinoma ............................................................................. 2 
1.1.2 Diagnosis and staging ........................................................................... 4 
1.1.3 CRC survival ......................................................................................... 6 
1.1.4 CRC treatment ...................................................................................... 8 
1.2 Stathmin-1 .................................................................................................... 9 
1.2.1 The Stathmin family ............................................................................... 9 
1.2.2 STMN1 in microtubule regulation ........................................................ 10 
1.2.3 STMN1 in cell cycle regulation ............................................................ 12 
1.2.4 STMN1 in cancer ................................................................................. 14 
 
Chapter 2 Objective of study ................................................................................. 15 
2.1 Motivation of study ...................................................................................... 16 
2.1.1 STMN1 up-regulation in metastatic CRC ............................................ 16 
2.1.2 Knowledge gaps and experimental aims ............................................. 20 
2.2 Workflow ..................................................................................................... 22 
 
Chapter 3 Results ................................................................................................... 25 
3.1 Stable STMN1 knockdown and over-expression ........................................ 26 
3.1.1 STMN1 knockdown ............................................................................. 28 
3.1.2 STMN1 over-expression ...................................................................... 30 
3.1.3 Summary ............................................................................................. 31 
3.2 STMN1 expression is required for metastatic processes in vitro ................ 33 
  iv   
 
3.2.1 Migration .............................................................................................. 34 
3.2.2 Invasion ............................................................................................... 36 
3.2.3 Adhesion ............................................................................................. 37 
3.2.4 Colony formation ................................................................................. 38 
3.2.5 Growth ................................................................................................. 39 
3.2.6 Summary ............................................................................................. 40 
3.3 STMN1 silencing regulates the metastatic proteome ................................. 41 
3.3.1 iTRAQTM Summary statistics ............................................................... 42 
3.3.2 Metastatic balance .............................................................................. 44 
3.3.3 Cell junctions and intracellular architecture ......................................... 46 
3.3.4 Apoptotic defense ................................................................................ 48 
3.3.5 Validation ............................................................................................. 50 
3.3.6 Summary ............................................................................................. 54 
3.4 STMN1 silencing enhances cellular anchorage and intracellular rigidity .... 55 
3.4.1 Hemidesmosomes ............................................................................... 56 
3.4.2 Desmosomes and intermediate filaments ........................................... 57 
3.4.3 Summary ............................................................................................. 58 
3.5 STMN1 silencing promotes 5-Fluorouracil sensitivity ................................. 59 
3.5.1 General cytotoxicity ............................................................................. 60 
3.5.2 5-Fluorouracil sensitisation .................................................................. 62 
3.5.3 Caspase-dependent apoptosis ............................................................ 64 
3.5.4 Caspase 6 activity ............................................................................... 66 
3.5.5 Summary ............................................................................................. 68 
3.6 STMN1 silencing regulates transcript abundance ...................................... 69 
3.6.1 p38 phosphorylation ............................................................................ 70 
3.6.2 Quality control ..................................................................................... 72 
3.6.3 CRC progression and cytoskeletal remodelling .................................. 74 
3.6.4 Metastatic and EMT transcriptional profile .......................................... 76 
3.6.5 Validation ............................................................................................. 79 
3.6.6 Summary ............................................................................................. 80 
3.7 Regulation of STMN1 function .................................................................... 81 
3.7.1 STMN1 interactions ............................................................................. 82 
3.7.2 Fibronectin stimulation ........................................................................ 86 
3.7.3 p53 dependence .................................................................................. 87 
3.7.4 STMN1 phosphorylation ...................................................................... 90 
3.7.5 S25/38 phosphorylation in metastatic processes ................................ 92 
  v   
 
3.7.6 Summary ............................................................................................. 94 
 
Chapter 4 Discussion ............................................................................................. 95 
4.1 Experimental strategy ................................................................................. 96 
4.2 STMN1 expression drives in vitro metastatic phenotype ............................ 97 
4.3 Molecular benefits of STMN1 silencing ...................................................... 99 
4.4 STMN1 interactions and S25/38 phosphorylation determine pro-metastatic 
activity....................................................................................................... 101 
4.5 STMN1 silencing regulates metastatic networks ...................................... 103 
4.6 STMN1 silencing: a potential therapy against metastatic CRC ................ 104 
 
Chapter 5 Conclusion and future work ............................................................... 107 
 
Chapter 6 Materials and methods ....................................................................... 110 
6.1 Cell lines and constructs ........................................................................... 112 
6.1.1 HCT116 and E1 cell lines .................................................................. 112 
6.1.2 Preparation of whole cell lysate ......................................................... 112 
6.1.3 STMN1 KD and OE constructs .......................................................... 113 
6.1.4 Mutagenesis ...................................................................................... 113 
6.1.5 Transfection ....................................................................................... 114 
6.2 Cell-based assays .................................................................................... 115 
6.2.1 Proliferation ....................................................................................... 115 
6.2.2 Wound healing .................................................................................. 115 
6.2.3 Transwell migration ........................................................................... 116 
6.2.4 Matrigel invasion ............................................................................... 117 
6.2.5 Cell adhesion ..................................................................................... 117 
6.2.6 Anchorage-independent colony formation ......................................... 118 
6.3 Proteome profiling .................................................................................... 119 
6.3.1 iTRAQTM: labeling chemistry.............................................................. 119 
6.3.2 iTRAQTM: sample preparation............................................................ 120 
6.3.3 iTRAQTM: 2D LC-MS/MS ................................................................... 121 
6.3.4 iTRAQTM: protein and peptide identification ....................................... 122 
6.3.5 iTRAQTM: data analysis ..................................................................... 123 
6.3.6 SWATHTM MS: label-free technology ................................................ 124 
6.3.7 SWATHTM MS: sample preparation and analysis .............................. 125 
6.3.8 SWATHTM MS: protein identification and quantitation ....................... 126 
  vi   
 
6.4 Transcript analysis .................................................................................... 127 
6.4.1 RNA extraction and quantification ..................................................... 127 
6.4.2 qPCR array ........................................................................................ 127 
6.5 Molecular methods ................................................................................... 128 
6.5.1 1D western blotting ............................................................................ 128 
6.5.2 2D western blotting ............................................................................ 129 
6.5.3 Dephosphorylation ............................................................................ 130 
6.5.4 Immuno-fluorescence ........................................................................ 131 
6.5.5 Cytotoxicity ........................................................................................ 132 
6.5.6 Flow cytometry .................................................................................. 132 
6.5.7 Caspase inhibition ............................................................................. 133 
6.5.8 Caspase 6 activity ............................................................................. 133 
6.6 Data representation .................................................................................. 135 
6.6.1 Graphs and data visualisation ........................................................... 135 
6.6.2 Images ............................................................................................... 135 
6.6.3 Statistical analyses ............................................................................ 135 
 
Appendix I: Proteins regulated by STMN1 silencing (iTRAQTM) ............................ 136 
Appendix II: Regulated proteins validated by SWATHTM ....................................... 142 
Appendix III: Transcripts regulated by STMN1 silencing (qPCR) .......................... 143 
 
Publications .......................................................................................................... 144 
Conference presentations.................................................................................... 145 
Awards ................................................................................................................... 146 
 
Bibliography .......................................................................................................... 148 
 
  
  vii   
 
List of Figures 
 
 
Chapter 1 Introduction 
Figure 1-1: Survival of primary and metastatic CRC   .................................................. 6
Figure 1-2: Stathmin family multiple sequence alignment   .......................................... 9
Figure 1-3: STMN1 regulates MT and mitotic spindle dynamics during cell cycle   ... 12
 
Chapter 2 Objective of study 
Figure 2-1: STMN1 is significantly up-regulated in hepato-metastatic cell line E1   .. 17
Figure 2-2: STMN1 expression increases with CRC progression   ............................ 18
Figure 2-3: STMN1 expression indicates CRC prognosis   ........................................ 19
Figure 2-4: Experimental workflow   ........................................................................... 23
 
Chapter 3 Results 
Figure 3-1: Representative colony amplified from a single stably-transfected cell   .. 28
Figure 3-2: Morphology of STMN1 KD and SC cells   ................................................ 29
Figure 3-3: Morphology of STMN1 OE and vector control cells   ............................... 30
Figure 3-4: Panel of stable STMN1 KD and OE cell lines   ........................................ 31
Figure 3-5: STMN1 expression is required for efficient wound healing   .................... 34
Figure 3-6: STMN1 expression promotes cell migration   .......................................... 35
Figure 3-7: STMN1 expression promotes matrix invasion   ....................................... 36
Figure 3-8: STMN1 expression inhibits cell adhesion   .............................................. 37
Figure 3-9: STMN1 expression promotes anchorage-independent growth   ............. 38
Figure 3-10: STMN1 expression confers no proliferative advantage   ....................... 39
Figure 3-11: Functional classification of targets regulated by STMN1 silencing   ...... 43
Figure 3-12: Hemidesmosomes   ............................................................................... 46
  viii   
 
Figure 3-13: Desmosomes   ....................................................................................... 47
Figure 3-14: iTRAQTM validation by western blotting   ............................................... 50
Figure 3-15: iTRAQTM validation by immuno-fluorescence   ...................................... 51
Figure 3-16: STMN1 silencing strengthens hemidesmosomes   ................................ 56
Figure 3-17: STMN1 silencing increases intracellular rigidity   .................................. 57
Figure 3-18: STMN1 silencing promotes sensitivity to MT inhibitors and 5FU   ......... 60
Figure 3-19: Microtubule inhibition and 5FU treatment decrease STMN1 level   ....... 61
Figure 3-20: STMN1 silencing amplifies 5FU-dependent apoptosis   ........................ 63
Figure 3-21: 5FU-induced apoptosis is caspase-dependent   .................................... 64
Figure 3-22: 5FU sensitisation in STMN1 KD cells depends on Caspases 3 and 6.   65
Figure 3-23: Caspase 6 activity amplifies 5FU sensitivity   ........................................ 66
Figure 3-24: Caspase 6 activation and cleavage of Lamin A   ................................... 67
Figure 3-25: Model of STMN1 silencing induced 5FU sensitisation   ......................... 68
Figure 3-26: p38 phosphorylation   ............................................................................ 70
Figure 3-27: qPCR reproducibility   ............................................................................ 73
Figure 3-28: STMN1 KD inhibits CRC progression and cytoskeletal remodelling   ... 74
Figure 3-29: STMN1 KD reverses metastatic and EMT transcriptional profile   ......... 77
Figure 3-30: qPCR validation by western blotting   .................................................... 79
Figure 3-31: STMN1 is enriched by immuno-precipitation   ....................................... 82
Figure 3-32: 2D separation of STMN1 IP eluate   ...................................................... 83
Figure 3-33: STMN1 potentially interacts with RhoGAP8   ........................................ 84
Figure 3-34: STMN1 may regulate G protein signaling   ............................................ 85
Figure 3-35: Fibronectin induces STMN1 expression   .............................................. 86
Figure 3-36: STMN1 silencing perturbs p53 transcirptional network   ....................... 87
Figure 3-37: Stable STMN1 silencing in HCT116 p53-/- cells   ................................... 88
Figure 3-38: Functional p53 not required to achieve efficacy of STMN1 silencing   .. 88
Figure 3-39: STMN1 is phosphorylated at S16, 25, 38 and 63 in CRC cells   ........... 90
Figure 3-40: Rescue of STMN1 KD by phosphorylation defective mutants   ............. 92
  ix   
 
Figure 3-41: STMN1 pro-metastatic activity depends on S25/38 phosphorylation   .. 93
 
Chapter 4 Discussion 
Figure 4-1: Structure of STMN1 protein (schematic)   ............................................. 101
Figure 4-2: Model of STMN1 inhibition in CRC   ...................................................... 105
 
Chapter 6 Materials and methods 
Figure 6-1: Wound healing insert   ........................................................................... 115
Figure 6-2: Transwell migration insert.   ................................................................... 116
Figure 6-3: Matrigel invasion chamber.   .................................................................. 117
Figure 6-4: iTRAQ labels   ....................................................................................... 119
Figure 6-5: iTRAQ reporter ions   ............................................................................. 120
Figure 6-6: iTRAQ sample pooling   ......................................................................... 120
Figure 6-7: iTRAQ experimental workflow.   ............................................................ 121
Figure 6-8: iTRAQ threshold filtering.  ..................................................................... 123
Figure 6-9: SWATH acquisition   .............................................................................. 124
 
  x   
 
List of Tables 
 
 
Chapter 1 Introduction 
Table 1-1: STMN1 up-regulation in cancer and disease   .......................................... 14
 
Chapter 3 Results 
Table 3-1: iTRAQTM summary statistics   .................................................................... 42
Table 3-2: STMN1 silencing upsets CRC metastatic balance   .................................. 44
Table 3-3: STMN1 silencing promotes cellular anchorage and intracellular rigidity   . 46
Table 3-4: STMN1 silencing tips the balance in favour of cell death   ........................ 48
Table 3-5: Verification of iTRAQTM data by SWATHTM MS   ....................................... 52
Table 3-6: RNA quality   ............................................................................................. 72
 
Chapter 6 Materials and methods 
Table 6-1: Mutagenesis primers   ............................................................................. 113
Table 6-2: Primary antibodies for western blotting.   ................................................ 128
Table 6-3: Secondary antibodies for western blotting.   ........................................... 129
Table 6-4: Immuno-fluorescence antibodies   .......................................................... 131
 













BLANK PAGE  




Colorectal carcinoma (CRC) is a perennial concern in public health. While primary 
lesions detected early are largely curable by surgical resection and peri-operative 
chemotherapy, metastatic spread contributes significantly to CRC-related deaths. 
Hence it follows that reducing loss of lives to CRC should involve metastatic 
inhibition and improving chemo-response.  
 
Based on a proteome comparison between isogenic primary and metastatic CRC 
cell lines, Stathmin-1 (STMN1) was found to be significantly up-regulated and 
associated with CRC metastasis. Clinically, high STMN1 expression was also highly 
correlated with CRC metastatic progression and strongly indicative of poor disease-
free survival. This work demonstrates that high STMN1 expression is sufficient to 
initiate metastatic processes in vitro, through promoting metastatic protein 
expression, as well as modulating oncogenic and mesenchymal transcription. 
STMN1 silencing on the other hand reinstates the default cellular programme of 
metastatic inhibition, and significantly improves chemo-response to 5FU through a 
novel caspase 6-dependent mechanism.  
 
Moreover, this work demonstrates that STMN1 function in metastatic processes may 
be further regulated at the expression level by chemo-attractant stimulation, at the 
interaction level through potential binding to RhoGAP8, and by phosphorylations at 
S25 or S38, which have profound consequences on migratory and invasive 
processes. These findings establish STMN1 as a potential target in anti-metastatic 
therapy, and demonstrate the power of an approach coupling proteomics and 
transcript analyses in the global assessment of treatment benefits and potential side-
effects.  





CRC   colorectal carcinoma 
EMT   epithelial-to-mesenchymal transition 
FDR   false discovery rate 
IF   intermediate filament 
iTRAQTM  isobaric tags for relative and absolute quantitation 
IPA   ingenuity pathway analysis 
KD   knockdown 
MT   microtubule 
OE   over-expression 
pI   iso-electric point 
SC   scrambled control 
S.D.   standard deviation 
S.E.   standard error 
STMN1  stathmin-1  
SWATHTM MS  sequential window acquisition of all th
TMA   tissue microarray 
eoretical mass spectra 
TBHP  tert-butyl hydroperoxide 
Vec  vector control 
2D-DIGE  two-dimensional difference gel electrophoresis 
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1.1 Colon cancer  
 
1.1.1 Colorectal carcinoma 
 
Colorectal carcinoma (CRC) is a perennial concern in public health1. According to 
yearly estimates from the American Cancer Society for the year 2013, more than 140 
thousand people in the United States alone are expected to develop CRC, and the 
estimated deaths from CRC and metastatic complications are projected to exceed 50 
thousand. CRC is thus likely to make up about 10% of all cancer incidence and 
mortality in 20132. Consistent with trends in developed countries, CRC is the most 
frequent cancer in Singapore, accounting for 14% to 18% of all cancer incidence 
between 2005-20093.  
 
Colorectal cancers usually begin as non-cancerous polyps in the inner lining of the 
colon or rectum4. Over many years, adenomatous polyps in the dysplasic colon may 
develop into pre-neoplastic lesions upon genetic, chemical or environmental trigger. 
Since more than 95% of all CRCs are adenocarcinomas, neoplastic polyps 
(adenomas) are frequently regarded as the earliest signs of possible CRC 
development. 
 
Numerous CRC risk factors have been proposed, and these may be categorised 
broadly into hereditary or lifestyle predispositions. Among the heritable factors, family 
history of colorectal polyps5 or inflammatory bowel disease6 are well-documented 
risks for developing CRC, while familial adenomatous polyposis (FAP)7  and 
hereditary non-polyposis colon cancer (HNPCC)8 are driven by heritable mutations. 
Lifestyle also significantly influences the odds of developing CRC. In particular, low 
fibre diet rich in red meat9 and lack of regular exercise10 appear to correlate closely 
with CRC incidence. Since physical inactivity, obesity, smoking and heavy alcohol 
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use are shared lifestyle risks between CRC and type II diabetes (T2D), patients with 
T2D also appear to be predisposed to CRC11.  
 
Various gene mutations have been reported to drive CRC development12. Inherited 
APC mutation causes FAP13 while defective DNA repair machinery (MLH1, MSH2) 
causes HNPCC14. Sporadic mutations in KRAS15 and TP5316 on the other hand are 
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1.1.2 Diagnosis and staging 
 
Given the asymptomatic nature of early lesions, CRC diagnosis has been a constant 
challenge. Up to 60 cm of the rectum and colon may be surveyed by flexible 
sigmoidoscopy17, while visual inspection of the entire colon is only possible with 
colonoscopy18, which remains the gold standard in detection of early colonic 
abnormalities. Virtual colonoscopic methods like double contrast barium enema19 
and CT colonography20 could also pick up potential cancerous lesions but the 
resolution is generally limited by accessibility of barium sulfate to early lesions and 
three-dimensional reconstruction of the inner colon surface. Since these often still 
require verification by standard colonoscopy, the utility of virtual colonoscopic 
techniques remains somewhat limited unless reducing invasiveness is critical. 
 
Other than imaging methods, analysis of fecal content could also indicate the 
presence of colonic abnormalities. Fecal occult blood test (FOBT) and fecal 
immunochemical test (FIT) detect the presence of blood in fecal matter21, and are 
completely non-invasive, but these generally cannot distinguish between cancerous 
lesions, or ulcers, haemorrhoid, diverticulosis and colitis due to benign conditions. In 
addition, these tests are also only sensitive against tumours that bleed, or advanced 
tumours that have invaded extensively into the colon wall. Stool DNA test could also 
detect the presence of mutations in abnormal cells that dislodge from growing 
tumours in the colon22. When any of the diagnostic tests turns up positive, biopsies 
may be obtained in follow-up colonoscopy or via laparoscopic techniques23 for 
confirmation and CRC staging. 
 
Accurate CRC staging requires physical examination, analysis of biopsies, as well as 
imaging tests like CT, MRI24 or PET scans. The most commonly used method of 
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CRC staging is the TNM system provided by the American Joint Committee on 
Cancer (AJCC). This method measures the extent of CRC progression by scoring 
the depth of tumour penetration into colonic wall (T), the extent of regional 
metastasis to the lymph nodes (N), and presence of metastatic spread to other 
organs (M)25. Based on such categorical scoring, the staging is complete when TNM 
parameters are combined and assigned a stage with Roman numerals. In general, 
localised CRC tumours are either Stage I or II depending on the depth of penetration, 
while Stage III involves lymph node metastasis, and Stage IV metastatic spread to 
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1.1.3 CRC survival 
 
Driven by nationwide campaigns to screen for CRC in individuals above the age of 
50, detection of CRC has improved significantly over the years26. Nonetheless, the 
challenge remains to prevent metastatic spread after surgery, which accounts 
significantly for CRC-related mortality worldwide1. According to five-year survival 
data obtained between 2002-2008 (Figure 1-1), as high as 90% of primary CRCs are 
curable by resection, but only 12% of patients with distant metastases survive 




Figure 1-1: Survival of primary and metastatic CRC. Figure reproduced with modifications from 
Cancer statistics 20132. 
 
Preventing CRC metastasis requires a precise molecular understanding of the 
metastatic progression. Given the complexity of metastatic signaling and multi-level 
regulation of metastatic balance, targeting the CRC metastatic cascade is extremely 
difficult, not to mention that a comprehensive assessment of possible side effects is 
grossly lacking. In the most ideal metastatic inhibition, targeting a single molecule at 
the crossroads of CRC metastatic cascades should reduce metastatic phenotype by 
blocking several pathways specific to tumour disseminative function.  
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Alternatively, preventing CRC metastasis may require early diagnosis and accurate 
prognosis, allowing the stratification of a patient sub-category at risk of accelerated 
tumour progression, or developing metastatic disease. These patients should then 
be screened at higher frequency compared to the normal recommendation, to make 
the earliest detection of metastasis. More aggressive treatment may also be 
justifiable at an early stage for these patients to improve the odds of survival. Yet, 
these approaches are not currently possible, since no reliable prognostic biomarkers 
are available to date.  
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1.1.4 CRC treatment 
 
CRC treatment may involve combinations of surgical resection, radiation therapy, 
chemotherapy or targeted therapy administered sequentially or simultaneously27. 
CRCs detected as localised tumours in Stages I and II generally require only surgical 
resection, while the benefit of adjuvant chemotherapy is controversial28, 29. Typically, 
open or laparoscopic-assisted colectomy30 is performed to remove the affected colon 
segment and neighbouring lymph nodes, while local excision during endoscopic 
examination is also possible to remove smaller lesions.  
 
In addition to surgical resection, peri-operative radiation and chemotherapy are 
generally prescribed for CRC patients in advanced stages. Chemical treatment 
regimes involving 5-Fluorouracil (5FU) in various combinations with leucovorin, 
oxaliplatin and irinotecan are used, with or without adjuvant radiotherapy31. 
Therapeutic antibodies against VEGF or EGFR 32, 33, as well as tyrosine kinase 
inhibitors30 are also in clinical use. Nevertheless, the efficacy of these approaches 
remain very limited against metastatic CRC, and novel treatment strategies are 











1.2.1 The Stathmin family 
 
The Stathmin (STMN) family consists of four members related by a highly conserved 
tubulin-interacting domain called the “stathmin-fold” (Figure 1-2). While STMN1 is 
ubiquitously expressed in the cytoplasm, STMN2 (superior cervical ganglion-10, 
SCG10), STMN3 (SCG10-like protein, SCLIP) and STMN4 (Stathmin-like protein B3, 
RB3) are exclusively present in the neuronal golgi complex34. Differences in 
distribution between STMN1 and the neuronal stathmins suggest distinct cellular 
functions, but all stathmins interact with tubulin to inhibit microtubule assembly. 
 
Figure 1-2: Stathmin family multiple sequence alignment. All stathmins share a conserved 
tubulin binding domain (“stathmin-fold”; shaded), while N-terminal sequences differ significantly. 
Identical residues are marked by asterisks; conserved residues marked by dot(s). 
 
Neuronal stathmins SCG10/STMN2 and SCLIP/STMN3 control neurite outgrowth35 
and neuronal cell projections36 respectively, while the function of neuronal 
RB3/STMN4 is less well characterized. The documented functions of STMN1 are 
described in detail in subsequent sections.  
CLUSTAL W (1.83) multiple sequence alignment 
 
sp|P16949|STMN1_HUMAN  MAS----------------------------------------------S 
sp|Q93045|STMN2_HUMAN  MAKTAMAYKEKMKELSMLSLICSCFYPEPRNINIYTY------------D 
sp|Q9H169|STMN4_HUMAN  M--TLAAYKEKMKELPLVSLFCSCFLADPLNKSSYKYEADTVDLNWCVIS 
sp|Q9NZ72|STMN3_HUMAN  MASTISAYKEKMKELSVLSLICSCFYTQPHPNTVYQY------------G 
                       *                                                . 
 
sp|P16949|STMN1_HUMAN  DIQVKELEKRASGQAFELILSPRSKES-VPEFPLSPPKKKDLSLEEIQKK 
sp|Q93045|STMN2_HUMAN  DMEVKQINKRASGQAFELILKPPSPIS-EAPRTLASPKKKDLSLEEIQKK 
sp|Q9H169|STMN4_HUMAN  DMEVIELNKCTSGQSFEVILKPPSFDG-VPEFNASLPRRRDPSLEEIQKK 
sp|Q9NZ72|STMN3_HUMAN  DMEVKQLDKRASGQSFEVILKSPSDLSPESPMLSSPPKKKDTSLEELQKR 
                       *::* :::* :***:**:**.. *  .  .    : *:::* ****:**: 
 
sp|P16949|STMN1_HUMAN  LEAAEERRKSHEAEVLKQLAEKREHEKEVLQKAIEENNNFSKMAEEKLTH 
sp|Q93045|STMN2_HUMAN  LEAAEERRKSQEAQVLKQLAEKREHEREVLQKALEENNNFSKMAEEKLIL 
sp|Q9H169|STMN4_HUMAN  LEAAEERRKYQEAELLKHLAEKREHEREVIQKAIEENNNFIKMAKEKLAQ 
sp|Q9NZ72|STMN3_HUMAN  LEAAEERRKTQEAQVLKQLAERREHEREVLHKALEENNNFSRQAEEKLNY 
                       ********* :**::**:***:****:**::**:****** : *:***   
 
sp|P16949|STMN1_HUMAN  KMEANKENREAQMAAKLERLREKDKHIEEVRKNKESKDPADETEAD 
sp|Q93045|STMN2_HUMAN  KMEQIKENREANLAAIIERLQEKERHAAEVRRNKELQVE----LSG 
sp|Q9H169|STMN4_HUMAN  KMESNKENREAHLAAMLERLQEKDKHAEEVRKNKELKEE----ASR 
sp|Q9NZ72|STMN3_HUMAN  KMELSKEIREAHLAALRERLREKELHAAEVRRNKEQREE----MSG 
                       ***  ** ***::**  ***:**: *  ***:*** :       :  
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1.2.2 STMN1 in microtubule regulation 
 
The role of STMN1 has been rigorously studied in the context of microtubule (MT) 
regulation37, 38. While interactions between tubulin and STMN2, STMN3 or STMN4 
were studied in relation to neuronal development39-41, studies on STMN1-tubulin 
interactions focused largely on its effect on MT assembly42-44. Consistent with the 
ubiquitous distribution of STMN1 in most cell types, the modulation on MT 
polymerization was deemed to be of universal significance. 
 
In a manner similar to the other Stathmins, STMN1 interacts with αβ-tubulin dimers 
at the helical “Stathmin-fold” to form complexes with defined stoichiometry (T2S)45. 
This effectively reduces the intracellular tubulin pool available for MT assembly, 
since STMN1 binding precludes the incorporation of these subunits into existing 
filaments46. It was alternatively suggested that STMN1 may also bind directly to ends 
of polymerizing MTs to inhibit further extensions47, or promote filament disassembly43, 
otherwise known as MT “catastrophe”48. 
 
Supported by crystal structures, STMN1-tubulin interactions are predominantly 
regulated by phosphorylation on 4 serine residues (S16, S25, S38, S63)49. Addition 
of phosphate groups at these sites interferes with tubulin binding, and directly frees 
up building blocks for extension of MT structures critically required in chromosomal 
segregation. While S16/S63 phosphorylations were reportedly the critical trigger to 
detach tubulin from STMN150, 51, conflicting data instead highlighting the importance 
of S38/S63 phosphorylation as priming events also exist42, 51, 52. Hence a consensus 
on the contribution of specific phosphorylative events controlling MT dynamics is still 
lacking.  
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Numerous kinases were reportedly responsible for STMN1 phosphorylations. These 
include CaM II, CaM IV, CDK1, CDK2, Kinase downstream of TNF, MAPK, PKA, 
PKG, p38delta and p65PAK37 but kinase specificity to each serine residue remains 
poorly mapped, and promiscuity is frequently reported. The complexity in phosph-
STMN1 regulation is also further compounded by PP2A phosphatase activity which 
may remove specific or all phosphates on STMN153. These phosphorylative changes 
heavily impact the role of STMN1 in MT regulation but require further work to yield 
conclusive evidence. 
 
MT regulation through STMN1 has been implicated in T-cell activation54, and 
endothelial permeability55, but no direct link was established with metastatic 
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1.2.3 STMN1 in cell cycle regulation 
 
Proper mitotic spindle assembly underlies the precise allocation of daughter 
chromosomes during cell division, and ensures that the catastrophic consequences 
of aneuploidy are avoided at all cost. MT filament assembly and dynamics are key 
modulators of anaphase chromosomal segregation, that in turn depend on STMN1 
regulation. Hence it follows that MT inhibitor STMN1 should also modulate cell cycle 
progression. 
 
Figure 1-3: STMN1 regulates MT and mitotic spindle dynamics during cell cycle. 
STMN1 controls cell cycle progression through MT regulation. Diagram generated 
based on ideas from Rubin et al., 200456. Cell cycle stages without requirement for 
STMN1 function are omitted for clarity. 
 
As shown in Figure 1-3, STMN1 controls numerous steps in the cell cycle. Prior to 
mitotic entry, disassembly of interphase MTs by STMN1 dephosphorylation allows 
tubulin subunits to be reassembled into the mitotic spindle47, while chromosomal 
capture and segregation during metaphase and anaphase depend heavily on the 
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exit similarly requires STMN1-mediated dissolution of the mitotic spindle and 
reconstitution of the interphase MTs57. Consistent with the critical role of STMN1 in 
MT regulation, both high and low expressions of STMN1 were reported to cause cell 
cycle arrest in different model systems52, 58.  
 
Nonetheless, there exists a conundrum in STMN1 expression. High level of STMN1 
reportedly inhibits cell cycle progression, yet cells with high proliferative potential 
also have high STMN1 level. It was reported that STMN1 expression is induced 
during liver regeneration59, and can reach ten times the normal level60. Shortage of 
intracellular STMN1 on the other hand also appears to affect MT-dependent events 
of cytokinesis, to result in polyploidy or the formation of multinucleated cells61. These 
findings contradict the inhibitory role of STMN1 in cell cycle progression, and allude 
to possible organ specificity in STMN1 function. This necessitates a careful 
measurement of STMN1-dependent growth effects in CRC, since differences in cell 
proliferation are likely to influence the experimental approach and affect most down-
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1.2.4 STMN1 in cancer 
 
Consistent with the role of STMN1 in MT and cell cycle regulation, it is intuitive that 
expression changes in STMN1 are highly conserved in various diseased states. 
STMN1 elevation was first documented in leukemia62, but was soon detected in a 
range of cancerous and disease conditions as shown in Table 1-1. 
 
Table 1-1: STMN1 up-regulation in cancer and disease. Representative 
publications between 1988 and 2013. First report of STMN1 up-regulation in 
CRC is shaded grey. 
Cancer/ Disease Publication 
Leukemia Hanash62, 1988 
Adenoid cystic carcinoma (salivary glands) Nakashima63, 2006 
Breast cancer Curmi64, 2000; Baquero65, 2012 
Ovarian cancer  Price66, 2000; Wei67, 2008 
Oral squamous-cell carcinoma Kouzu68, 2006 
Prostate cancer Ghosh69, 2007 
Medulloblastoma Kuo70, 2009 
Liver cancer Gan71, 2010 
Colorectal cancer Tan72, 2012 
Myelodysplastic syndrome Machado-Neto73, 2013 
Nasopharyngeal carcinoma Hsu74, 2013 
Gastric cancer Jeon75, 2010; Ke76, 2013 
Cervical cancer Xi77, 2009; Howitt78, 2013  
Melanoma Chen79, 2013 
Urothelial carcinoma (bladder) Bhagirath80, 2013 
 
 
Despite implication in a wide range of diseases, most of these published work merely 
documented increased expression or reported diagnostic significance of STMN1. In 
2012, STMN1 expression was first linked to CRC prognosis (Table 1-1), but the 
functional relevance of STMN1 to CRC progression and the mechanism of STMN1 
dependent metastatic processes remain to be dissected. Since STMN1 up-regulation 
is a common trait in many cancers, molecular understanding of STMN1 function 
derived from studying the CRC system may potentially also apply to other diseased 
states.   
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Chapter 2 Objectives of study 
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2.1 Motivation of study 
 
2.1.1 STMN1 up-regulation in metastatic CRC 
 
To identify expression changes associated with CRC metastasis, a quantitative 
proteome comparison between primary (HCT116) and metastatic (E1) CRC cell lines 
was performed by two-dimensional difference gel electrophoresis (2D-DIGE)72. 
Comparing between these iso-genic cell lines, STMN1 was identified as one of the 
most up-regulated proteins in the E1 cell line (Figure 2-1), suggesting that it could be 
functionally important in the CRC metastatic cascade.  
 
Subsequent validation established that STMN1 up-regulation is conserved in other 
metastatic CRC cell lines72, and that strong STMN1 immuno-staining in clinical 
samples correlated with CRC disease progression (Figure 2-2). When STMN1 
expression was further analysed in 324 patient samples in tissue microarray (TMA) 
format, high STMN1 expression was again strongly associated with poor disease 
outcome based on survival data (Figure 2-3).  
 
These early work established STMN1 as a potential CRC prognostic biomarker and 
implicated STMN1 in the CRC metastatic process. Such findings fueled the interest 
to further investigate the functional significance of STMN1 in CRC metastasis.  
 
 




Figure 2-1: STMN1 is significantly up-regulated in hepato-metastatic cell line E1. Proteome comparison between primary CRC cell line HCT116 and its metastatic 
derivative cell line E172. STMN1 was identified as one of the most up-regulated proteins in the metastatic cell line (STMN1 isoforms indicated by red box). Up- and down-
regulated proteins are represented in red and green respectively.   






Figure 2-2: STMN1 expression increases with CRC progression. STMN1 up-regulation with CRC progression was demonstrated by immuno-
histochemistry72. Metastatic spread to lymph node constitutes “regional metastasis”, while the formation of secondary tumour at a distant site is 
considered “distant metastasis”. 
 




Figure 2-3: STMN1 expression indicates CRC prognosis. Patients staining negative for STMN1 had significantly 
better five-year survival rate compared to patients with low, moderate or high STMN1 expression (* p=0.013)72. 
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2.1.2 Knowledge gaps and experimental aims 
 
 
Several bottlenecks limiting the treatment of metastatic CRCs were identified in the 
introduction (Section 1). These include:  
(i)  Poor understanding of CRC metastatic progression,  
(ii) Need for a single target to inhibit multiple disseminative cascades,  
(iii)  Shortage of prognostic biomarkers to improve prediction of CRC outcome,  
(iv)  Ineffective treatment against metastatic CRC, and  
(v)  Lack of methods for global assessment of treatment side effects. 
 
In an attempt to bridge these knowledge gaps, the following experimental aims are 
proposed in this study: 
(A) To investigate the functional role of STMN1 in CRC metastasis, 
(B) To assess if targeting STMN1 expression inhibits CRC disseminative 
cascades, 
(C) To validate the prognostic significance of STMN1 up-regulation in CRC 
disease progression, 
(D) To test if STMN1 may be targeted to improve chemo-response in metastatic 
CRC, 
(E) To employ a proteomics/transcript analysis approach for global assessment 
of benefits and potential side effects associated with STMN1 targeting, 
(F) To establish a link, if any, between STMN1 phosphorylation and metastatic 
phenotype, and 
(G) To understand how STMN1 expression and function is regulated in CRC. 
 
 
Achieving these goals should contribute to predicting and reducing CRC metastatic 
spread, as well as improving chemo-response and limiting loss of lives associated 
with CRC metastasis.  
  




Driven by the prognostic significance of STMN1 up-regulation in CRC progression72, 
the function of STMN1 in metastatic processes was investigated by a series of 
experiments presented in Section 3.  
 
Figure 2-4 summarises the experimental approach beginning with the generation of 
cell line models (Section 3.1). The effect of STMN1 level on metastatic phenotype 
was assessed by various cell-based assays (Section 3.2), and metastatic changes 
were supported by expression differences identified from iTRAQ-based proteome 
analysis (Section 3.3). Two new hypotheses were also formulated based on iTRAQ 
data, which were tested in Sections 3.4 and 3.5.  
 
The changes in transcript abundance induced by STMN1 silencing were also 
measured for possible reversal of metastatic and mesenchymal transcriptional 
profiles (Section 3.6). Finally, returning to the source of STMN1 up-regulation, the 



















Figure 2-4: Experimental workflow. 
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3.1 Stable STMN1 knockdown and over-expression  
 
 
This section details the generation of stable STMN1 knockdown (KD) and over-
expression (OE) models in a pair of CRC cell lines with different metastatic 
potential81. Parental cell line HCT116 is a well-established CRC model cell line with 
low metastatic potential, while the strongly metastatic cell line E1 was derived from 
liver-specific metastases of HCT116 cells harvested from nude mouse. These KD 
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3.1.1 STMN1 knockdown  
 
Silencing of STMN1 was performed in HCT116 and E1 cells using commercial 
shRNA vectors as described in Sections 6.1.3 and 6.1.5. Uptake and transient 
silencing of STMN1 expression were monitored 2 days post transfection, while cells 
with stable integration of STMN1 silencing cassette were selected with puromycin for 




Figure 3-1: Representative colony amplified from a single stably-transfected cell. 
Transfected cells grow under selection to form well-defined single colonies (black 
arrow), while untransfected cells (white arrows) are eliminated by 1 µg/ml puromycin. 
 
As shown in Figure 3-1, stably transfected cells proliferated actively under selection 
to form well-defined single colonies by 2 weeks post transfection, while 
untransfected cells were eliminated within the first week of selection. Close of 90% of 
all colonies resistant to puromycin showed reduction in STMN1 expression based on 
western blotting (data not shown). The morphology of stable STMN1 knockdown (KD) 
and scrambled control (SC) cells are shown in Figure 3-2. 
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Figure 3-2: Morphology of STMN1 KD and SC cells. Representative images.Cells 
were seeded at equal density with 1 µg/ml puromycin selection and allowed 3 days to 
reach about 70% confluency. HKD and EKD refer to clones with stable STMN1 
knockdown, while HSC and ESC refer to control clones with stable integration of the 
scrambled shRNA sequence. 
 
In the primary colon carcinoma cell line HCT116, stable STMN1 silencing appeared 
to promote regular arrangement of cells in mono-layer culture (Figure 3-2, top panel), 
while stable STMN1 KD in the metastatic E1 cell line appeared to reduce dispersion 
between cells (Figure 3-2, bottom panel). 
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3.1.2 STMN1 over-expression  
 
Over-expression of STMN1 was similarly performed in HCT116 and E1 cells using 
commercial expression vector and empty vector control as described in Sections 
6.1.3 and 6.1.5. Uptake and transient expression of STMN1 were monitored 2 days 
post transfection, while cells with stable integration of STMN1 over-expression 
cassette were selected with G418 for 4 weeks, and screened periodically for 
expression of STMN1-DDK. Single colonies obtained after selection were similar to 
Figure 3-1 shown above. 
Unlike in puromycin selection, G418 selection was significantly less potent, where 
only about 50% of all colonies resistant to G418 expressed STMN1-DDK to levels 
detectable by western blotting (data not shown). The morphology of stable STMN1 
over-expression (OE) and vector control (vec) cells are shown in Figure 3-3. 
 
Figure 3-3: Morphology of STMN1 OE and vector control cells. Representative 
images. OE and respective vector control cells were seeded at equal cell density with 
400 µg/ml G418 selection and allowed 3 days to reach about 70% confluency. HOE 
and EOE refer to clones with stable STMN1 over-expression, while Hvec and Evec 
refer to control clones with stable incorporation of the empty vector. 




Stable STMN1 knockdown (KD) and over-expression (OE) cells were successfully 
generated in primary colon carcinoma cell line HCT116 and the metastatic-derived 
cell line E1. The respective scrambled control (SC) and vector control (vec) cell lines 
were also maintained separately with puromycin or G418 selection, in conditions 
identical to those used in KD and OE cells.  
 
Figure 3-4: Panel of stable STMN1 KD and OE cell lines. Total cell lysates 
were prepared as described in Section 6.1.2, and 20 µg total protein was 
loaded in each lane. Over-expressed STMN1 (“STMN1-DDK”) is tagged with 
Myc-DDK double tag which adds a mass of 4 kDa. 
 
These cell line models are used in subsequent investigations to elucidate the 
functional role of STMN1 in colorectal cancer metastasis. Expression of endogenous 
STMN1 and/or STMN1-DDK in each cell line is shown in Figure 3-4.  
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This section describes the effect of STMN1 level on various metastatic processes 
from cell migration and invasion, to cell adhesion and growth, both in monolayer or 
three-dimensional culture systems. These experimental findings support a functional 
role for STMN1 in CRC metastasis and serve to justify the invariant STMN1 up-
regulation observed with CRC progression. 
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3.2.1 Migration  
 
Since high STMN1 expression was positively correlated with advanced and 
metastatic CRC, the effect of STMN1 expression on cell migration was investigated 
by two in vitro methods. For qualitative assessment of cell migration, a wound 
healing assay was performed as described in Section 6.2.2. 
 
Figure 3-5: STMN1 expression is required for efficient wound healing. 
Efficiency of wound healing was positively correlated with STMN1 level (n=3). 
Detailed experimental parameters are found in Section 6.2.2.  
 
As shown in Figure 3-5, STMN1 OE in HCT116 cells clearly promoted wound 
healing processes (A) compared to vector control (B), while STMN1 KD in metastatic 
E1 cells  significantly blocked the ability to close a wound gap where epithelial-like 
projections were observed instead (C), compared to scrambled control (D). Assay 
conditions and durations were optimised such that poorly metastatic HCT116 vector 
control (B) showed no wound closure, while the metastatic E1 scrambled control (D) 
showed complete wound closure within the experimental period. 
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Figure 3-6: STMN1 expression promotes cell migration. (A-B) STMN1 over-
expression in HCT116 cells significantly increased transwell migration (** p<0.01), while 
(C-D) STMN1 silencing in metastatic cell line E1 drastically reduced cell migration  (*** 
p<0.001). The experiment was repeated and the transwell migration was plotted as 
mean ± S.E. (n=3). Detailed experimental parameters are found in Section 6.2.3. 
 
To further assess and verify the effect of STMN1 expression on cell migration, a 
quantitative transwell migration assay was performed as described in Section 6.2.3. 
As shown in Figure 3-6, STMN1 level noticeably affected cell migration in HCT116 
and E1 cells. Stable STMN1 OE in HCT116 significantly increased transwell 
migration (A) with respect to vector control (B) (** p<0.01), while stable STMN1 KD 
strongly inhibited migratory processes (C) compared to control cells (D) (*** p<0.001). 
These quantitative changes in cell migration corroborate well with qualitative 
assessment of wound healing, and suggest that STMN1 expression may be 
essential for efficient migratory processes in CRC cell lines.  
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3.2.2 Invasion  
 
The effect of STMN1 level on cellular invasive properties was also investigated using 
an in vitro matrigel invasion assay as described in Section 6.2.4. As shown in Figure 
3-7, STMN1 OE in weakly invasive HCT116 cell line was found to increase cell 
invasion significantly (*** p<0.001) (A-B), while STMN1 KD in E1 cells strongly 
abrogated invasive processes (C-D) (** p<0.01). 
 
 
Figure 3-7: STMN1 expression promotes matrix invasion. (A-B) STMN1 over-
expression in weakly invasive HCT116 cells significantly increased matrigel invasion 
(*** p<0.001), while (C-D) STMN1 silencing in metastatic cell line E1 correspondingly 
reduced cellular invasive properties  (** p<0.01). The experiment was repeated and 
the matrigel invasion was plotted as mean ± S.E. (n=3). Detailed experimental 
parameters are found in Section 6.2.4.  
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3.2.3 Adhesion  
 
The influence of STMN1 level on cell adhesion was also investigated by an adhesion 
assay as described in Section 6.2.5. As shown in Figure 3-8, STMN1 OE in HCT116 
significantly reduced adherent cells following 40 min incubation in fibronectin-coated 
wells (A-B) (*** p<0.001), while STMN1 KD in metastatic cell line E1 resulted in 
noticeable increase in cell adhesion (C-D) (** p<0.01). 
 
Figure 3-8: STMN1 expression inhibits cell adhesion. (A-B) STMN1 over-
expression in primary colon carcinoma cell line HCT116 observably interfered with 
cell adhesion (*** p<0.001), while (C-D) STMN1 silencing in metastatic cell line E1 
significantly augmented cellular adhesive properties  (** p<0.01). The experiment 
was repeated and the number of attached cells was plotted as mean ± S.E. (n=3). 
Detailed experimental parameters are found in Section 6.2.5. 
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3.2.4 Colony formation  
 
The ability of STMN1 KD and OE cells to form spheroids in 3D culture was also 
tested. Anchorage-independent growth was assessed by the number of colonies 
formed in soft agar after inoculation with a standardised number of cells. As shown in 
Figure 3-9, STMN1 OE in HCT116 cells drastically increased colony formation (*** 
p<0.001) (A-B), while STMN1 KD in metastatic E1 cells significantly reduced 
anchorage-independent colony formation (C-D) (** p<0.01). 
 
 
Figure 3-9: STMN1 expression promotes anchorage-independent growth. 
(A-B) STMN1 over-expression in poorly tumorigenic HCT116 cells significantly 
increased the capacity for anchorage independent colony formation (*** p<0.001), 
while (C-D) STMN1 silencing in malignant E1 cells evidently reduced 
tumorigenicity  (** p<0.01). The experiment was repeated and the number of 
colonies was plotted as mean ± S.E. (n=4). Detailed experimental parameters are 
found in Section 6.2.6.  
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3.2.5 Growth  
 
While high STMN1 level promotes metastatic processes like migration, invasion and 
colony formation, proliferative processes appear not to be affected by STMN1 KD or 
OE. As shown in Figure 3-10, the doubling rates of STMN1 KD cells were not 
significantly different from control cells (A). STMN1 OE also had no significant effect 
on cell proliferation (B). These serve as further confirmation that differences in 
metastatic processes observed in Sections 3.2.1 to 3.2.4 are not confounded by 
growth differences.  
 
Figure 3-10: STMN1 expression confers no proliferative advantage. (A) 
STMN1 silencing does not significantly alter proliferation rate in HCT116 and 
E1 cells (NS), while (B) STMN1 over-expression also had no observable effect 
on cell growth in both cell lines (NS). The experiment was performed in 7-
replicates, and cell doubling was plotted as mean ± S.E. (n=3). Detailed 
experimental parameters are found in Section 6.2.1.  




As shown in Section 3.2, STMN1 expression positively regulates CRC metastatic 
processes in vitro. STMN1 OE in both HCT116 and E1 cells significantly promoted 
migration, invasion, loss of adhesion as well as anchorage-independent colony 
formation, while STMN1 KD conversely suppressed the same metastatic processes. 
These observations seem to implicate STMN1 in CRC metastatic dissemination.  
 
Based on these in vitro experiments in KD and OE systems, two important 
implications become evident. Firstly, STMN1 may simultaneously regulate metastatic 
processes at both the primary and metastatic sites. This is because loss of adhesion 
at the primary site coupled to increase in migration and invasion is likely to facilitate 
detachment from tumour mass and increase access to blood circulation, while 
stronger tendency to form colonies should enable metastatic cells to re-establish with 
greater ease at the metastatic site. Secondly, high STMN1 level may be a metastatic 
trigger in CRC, since STMN1 OE alone is sufficient to induce a strong metastatic 
phenotype even in the weakly metastatic HCT116 cell line. These initial observations 
outline the need to further characterise STMN1 function, to better understand the 
mechanism of STMN1 dependent metastatic processes.  
 
Since linking cellular phenotype to mechanistic regulation in a hypothesis-driven 
manner is extremely difficult for poorly studied protein targets, a hypothesis-free 
proteomics approach was adopted next to describe STMN1 function with higher 
resolution and wider coverage.  
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3.3 STMN1 silencing regulates the metastatic proteome  
 
 
This section details the proteome analysis of HCT116 and E1 STMN1 KD cells 
(denoted by HKD and EKD respectively) in comparison to scrambled control cells 
(denoted by HSC and ESC respectively). Proteome changes identified by iTRAQTM 
were consistent with changes in metastatic phenotype observed experimentally, and 
validated  by western blotting, immuno-fluorescence or label-free SWATHTM MS. 
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3.3.1 iTRAQTM Summary statistics  
 
To elucidate the molecular basis for loss of metastatic phenotype induced by STMN1 
silencing, the total proteomes of HKD and EKD cells were profiled by an iTRAQTM 
labeling approach against control cells HSC and ESC. To avoid technical details in 
the results section, iTRAQTM labeling chemistry and labeling strategy are outlined 
separately in Sections 6.3.1 and 6.3.2, while parameters used in 2D-LC MS/MS and 
protein identification are described in Sections 6.3.3 and 6.3.4 respectively. 
 
Table 3-1: iTRAQTM summary statistics. A two-step filtering was performed to 
identify biologically meaningful differential regulations as a result of STMN1 silencing. 
False discovery rate (FDR) was restricted to 1%.  
Sequential filtering criteria Total number of proteins  Percentage 
Total identified (1% FDR) 4562 100 
→ Significantly and consistently regulated 192 4.21 
→ Curated and exist at protein level 139 3.05 
→ Up-regulated (>1.3) 82 1.80 
→ Down-regulated (<0.77) 57 1.25 
 
 
In this experiment, a total of 4562 proteins were identified and quantified based on 
relative iTRAQTM label intensity (Table 3-1). To enrich for meaningful expression 
changes, the dataset was further restricted based on (I) significant fold change in 
protein abundance and (II) biological consistency. Threshold fold change for 
significance was previously estimated to be  ≥1.3 and ≤0.77 for up - and down-
regulation respectively82, while biological consistency refers to similarity in regulation 
between HKD:HSC and EKD:ESC. The need to maintain consistency in fold change 
was intuitive, since both HKD and EKD cells appeared to lose metastatic phenotype 
upon STMN1 KD. By applying these two criteria, 192 targets (4.21%) remained with 
possible contribution to loss of metastatic phenotype in STMN1 KD cells. 
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Among these potential regulated targets, 53 were matched to UniProt/TrEMBL 
database based on detection at transcript level only, and were excluded from 
analysis, since the presence of these gene products at the protein level was not 
verified experimentally. The remaining 139 candidate proteins (3.05%) matched to 
entries in Uniprot/SWISSPROT database, where all entries are curated and shown 
to exist at the protein level. In total, the abundance of 82 protein targets (1.80%) 
were increased, and 57 (1.25%) decreased. All iTRAQTM summary statistics are 
tabulated in Table 3-1.  
 
Figure 3-11: Functional classification of targets regulated by STMN1 silencing. Molecular 
functions of 139 proteins significantly regulated by STMN1 silencing were manually annotated 
by literature review and documented only when at least two independent publications suggest 
similar molecular function. Where inconclusive molecular function was encountered (<2 pieces 
of published evidence), targets were categorized as with unknown function. For full list of 
regulated proteins, please refer to Appendix I. 
 
All 139 protein targets regulated by STMN1 silencing were annotated by extensive 
literature review as described in Section 6.3.5., and shown to function predominantly 
in metastatic processes, signaling, and cell death/apoptosis (Figure 3-11). Changes 
in these functional aspects are consistent with loss of metastatic phenotype 
observed experimentally (Section 3.2), and in turn suggest that STMN1 silencing 
possibly inhibits experimental metastasis through modulating these  processes. 
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3.3.2 Metastatic balance  
 
Metastatic phenotype is likely to be influenced by the balance between metastatic 
triggers and inhibitors. In the proteome comparison between STMN1 KD and SC 
cells, differential abundance of various proteins that regulate metastatic balance 
were detected (Table 3-2).  
 
Metastatic proteins Git1, RACK1, S100A10 and S100A6 were down-regulated in 
STMN1 KD cells. Git1 increases cell migration by targeting Pak1 to leading edge of 
lamellipodia83, and binds paxilin to regulate focal adhesion disassembly84. RACK1, 
on the other hand, promotes cell migration through physical interaction with RhoA85, 
and is required for paxilin/talin dynamics86. S100A10 promotes cell migration by 
directly regulating actin cytoskeletal structures87, while S100A6 is a Ras responsive 
gene heavily implicated in invasive metastasis88, that is invariably over-expressed at 
invading fronts of primary CRC lesions and liver metastases89. The coordinated 
down-regulation of all these metastatic proteins are consistent with loss of metastatic 
phenotype in STMN1 KD cells documented in Section 3.2. 
 
Table 3-2: STMN1 silencing upsets CRC metastatic balance. STMN1 silencing significantly 
reduced the expression of metastatic proteins GIT1, RACK1, S100A10 and S100A6, while 
increasing the expression of metastatic inhibitors ADAM15, SERPINB5, Hugl1 and NCK1. 
Targets with independently validated expression levels are shown in bold. 







117:118   
(HKD:HSC) 
IPI00384861 42.2 GIT1 4 0.75 0.65 
IPI00848226 91.8 RACK1 73 0.69 0.53 
IPI00183695 66 S100A10 4 0.48 0.70 
IPI00027463 83.3 S100A6 17 0.25 0.77 
IPI00969145 13 ADAM15 3 2.99 3.10 
IPI00783625 73.9 SERPINB5 18 2.38 1.56 
IPI00854741 38.2 Hugl1 10 1.64 1.38 
IPI00028065 43.2 NCK1 3 1.39 1.38 
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Moreover, inhibition on metastatic events may be further reinforced by concomitant 
up-regulation of metastatic inhibitors ADAM15, SERPINB5, CD109, Hugl1 and NCK1 
(Table 3-2). ADAM15 is a well-characterised tumour suppressor90 that strongly 
inhibits migration, invasion and anchorage-independent growth91. SERPINB5 
suppresses tumour induction, metastasis and invasion92, while CD109 promotes the 
internalization and degradation of TGFβ receptors, thereby abrogating TGFβ-
dependent metastatic signaling93. Loss of Hugl1 is known to contribute to CRC 
progression94 and is a marker of metastasis95, while NCK1 actively blocks Ras 
signaling96 and cell migration through cdc42-dependent JNK activation97. The 
collective up-regulation in metastatic inhibitors after STMN1 silencing thus suggests 
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3.3.3 Cell junctions and intracellular architecture  
 
iTRAQTM also detected significant expression changes in proteins that make up cell 
junctions and determine intracellular cytoskeletal architecture (Table 3-3).  
Table 3-3: STMN1 silencing promotes cellular anchorage and intracellular rigidity. STMN1 
silencing significantly promoted the expression of cell junction (ITGA6, ITGB4, LAMA5) and 
intermediate filament proteins (KRT1, KRT9, LAMA5). Targets with independently validated 
expression levels are shown in bold. 







117:118   
(HKD:HSC) 
IPI00019359 44.1 KRT9 15 36.31 1.46 
IPI00220327 63.2 KRT1 32 11.17 1.45 
IPI00013933 64.6 DSP 52 1.54 1.38 
IPI00921080 43.5 ITGA6 11 1.54 1.31 
IPI00220845 48 ITGB4 52 2.27 1.33 
IPI00783665 20.4 LAMA5 4 1.38 1.87 
       
Components of hemidesmosomal complexes (ITGA6, ITGB4 and LAMA5) were 
significantly increased after STMN1 KD. These basal junctions serve as docking 
points between epithelial cells and the basement membrane, and constitute a subtle 
defense against cell detachment and blood-borne dissemination98. ITGA6/ITGB4 
form a specific integrin-pair that is found uniquely at hemidesmosomes99 (Figure 3-
12) and the over-expression of ITGA6/ITGB4 reportedly enhances cell adhesion100. 
Increasing LAMA5 expression also promotes static adhesion and hemidesmosome 
formation, by serving as the docking site101.  
 
Figure 3-12: Hemidesmosomes. Image obtained from http://www.erin.utoronto.ca with modifications. 
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On the other hand, STMN1 silencing also possibly increases desmosomal tethering 
by increasing the expression of KRT1, KRT9 and DSP (Table 3-3). Desmosomes are 
lateral cell-junctions that bind neighbouring cells together in the same tissue layer, to 
prevent single cells from dislodging and becoming free102 (Figure 3-13). 
Desmosomes have acquired a newly appreciated role in tumour suppression, and 
down-regulation of desmosomal junctions was proposed to drive tumour 
development and early invasion103. KRT1/KRT9 form intracellular intermediate 
filaments (IFs) that are nucleated at DSP plugs found in desmosomes104. Increase in 
KRT1/KRT9 IFs was also proposed to enhance intracellular rigidity, a characteristic 
inversely correlated with malignancy105. 
 
 






  48   
 
3.3.4 Apoptotic defense  
 
Based on changes in protein expression, STMN1 KD also seemed to reduce 
apoptotic defense and tip the balance in favour of cell death (Table 3-4). The 
expression of cytoprotective proteins PI-9, MGST1 and APRIL were significantly 
suppressed in STMN1 KD cells. PI-9 is an inhibitor of Granzyme B that protects 
against Granzyme B mediated apoptosis in cancer cells106. MGST1 is a glutathione 
transferase that confers chemoresistance to cytostatic drugs107, and participates in 
direct detoxification as well as downstream protection against oxidative stress108. 
APRIL is a negative regulator of Caspase 3 dependent apoptosis109. The concerted 
down-regulation of all these anti-apoptotic proteins by STMN1 silencing supports a 
probable increase in chemo-sensitivity. 
 
Table 3-4: STMN1 silencing tips the balance in favour of cell death. STMN1 silencing 
significantly reduced the expression of proteins involved in apoptotic defense (PI-9, MGST1, 
APRIL), while increasing the expression of proteins that potentiate cell death (CASP6, SGPL1, 
ANT3). Markers of tumour cell robustness (NOP2, HIP1R) were also significantly reduced after 
STMN1 silencing. Targets with independently validated expression levels are shown in bold. 







117:118   
(HKD:HSC) 
IPI00032139 66.8 PI-9 16 0.72 0.62 
IPI00021805 29 MGST1 4 0.65 0.62 
IPI00007423 42.2 APRIL 23 0.39 0.62 
IPI00023876 43.3 CASP6 4 2.70 2.36 
IPI00099463 48.9 SGPL1 11 1.87 1.31 
IPI00291467 92 ANT3 36 1.33 1.66 
IPI00294891 55.8 NOP2 17 0.75 0.71 
IPI00024417 50.2 HIP1R 11 0.68 0.64 
       
 
On the other hand, STMN1 silencing also appears to amplify death signals through 
elevating the expression of Caspase 6, SGPL1 and ANT3 (Table 3-4). Although 
Caspase 6 is frequently regarded as an initiator caspase, recent evidence suggests 
that Caspase 6 may also function as an executioner caspase in colon cancer cells110. 
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Higher Caspase 6 expression was also reportedly sufficient to lower cell death 
threshold in response to apoptotic signals that cause its activation111. Increased 
SGPL1 also likely promotes apoptotic sensitization through sphingosine-1-phosphate 
cleavage and ceramide accumulation112. ANT3 on the other hand is a pro-apoptotic 
regulatory component of the mitochondrial permeability transition pore (mtPTP)113 
which increases mitochondrial permeability during apoptosis114. Hence, up-
regulations in Caspase 6, SGPL1 and ANT3 in STMN1 KD cells are likely to amplify 
death signals further in the context of weakened apoptotic defense described above. 
 
Therefore, STMN1 silencing appears to promote cell death sensitization at the 
expression level, by tilting the balance in favour of apoptotic execution. General 
markers of tumour robustness like NOP2115 and HIP1R116 were also down-regulated 
by STMN1 silencing, although no apparent inhibition on cell growth was observed 
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3.3.5 Validation  
 
The reliability of iTRAQTM quantitation was verified by western blotting (Figure 3-14), 
immuno-fluorescence (Figure 3-15) or label-free SWATHTM MS (Table 3-5). Antibody 
availability and type determined if western blotting with denaturation, or immuno-
fluorescence under native conditions was more suitable, while the validation of target 
proteins without commercially available antibodies required a quantitative label-free 
SWATH MS method. In total, 18 protein targets were validated by at least one of 
three chosen methods. Among these, S100A6, MGST1 and PI-9 were validated by 
two independent approaches, while regulation of S100A10 was demonstrated using 
all three methods. These clearly demonstrate the reliability of iTRAQTM quantitation. 
 
Figure 3-14: iTRAQTM validation by western blotting. Selected 
target proteins regulated by STMN1 silencing, as identified by 
iTRAQTM, were validated by western blotting in the original pooled 
lysates used for discovery (“iTRAQ”), in lysates from an independent 
passage (“validation set”), as well as in a transiently transfected 
STMN1 KD set (“transient set”). Antibody information, dilutions and 
detailed parameters used are found in Section 6.5.1. 





Figure 3-15: iTRAQTM validation by immuno-fluorescence. Images of STMN1 and RACK1 staining in E1 cells were obtained from the same field with double 
staining; similarly for Hugl1 and S100A10. Horizontal bar indicates 50 µm. Representative image (n=3). Similar data was obtained in HCT116 STMN1 KD cells. 





     
 
52 
Table 3-5: Verification by SWATHTM MS. Targets found regulated in iTRAQ experiment are in bold. Targets found 
regulated in qPCR experiment are underlined
Data set 
. Significance of KD/SC fold change was assessed by two-sample t-
test (equal variance). For  SWATHTM raw data, please refer to Appendix II. 
Protein ID Target 
STMN1 KD (n=4) STMN1 SC (n=4) KD/SC 
Mean peak area 
(±  s.d.) / E+04 
Mean peak area 
(±  s.d.) / E+04 Fold change P-value 
       
EKD-ESC 
IPI00220327 KRT1 13.64 (± 0.84) 7.03 (± 0.67) 1.94 1.77E-05 
IPI00291467 ANT3 26.63 (± 0.70) 15.33 (±0.37) 1.74 1.26E-07 
IPI00783625 SERPINB5 8.74 (± 1.42) 5.05 (±0.64) 1.73 3.24E-03 
IPI00019359 KRT9 0.69 (± 0.16) 0.41 (±0.12) 1.67 3.31E-02 
IPI00220847 ITGB4 9.19 (± 0.31) 5.54 (± 0.80) 1.66 1.44E-04 
IPI00759824 APRIL 15.09 (± 0.12) 21.08 (± 0.64) 0.72 1.66E-06 
IPI00784414 STAT3 1.13 (± 0.17) 2.13 (± 0.34) 0.53 1.98E-03 
IPI00984539 CD44 11.41 (± 0.82) 26.00 (0.42) 0.44 
IPI00921996 
6.66E-08 
STMN1 2.34 (± 0.79) 28.91 (± 0.54) 0.08 2.33E-09 
       
HKD-HSC 
IPI00921401 ITGA6 6.81 (± 0.08) 4.03 (± 0.58) 1.69 7.62E-05 
IPI00783625 SERPINB5 5.94 (± 0.64) 4.26 (± 1.00) 1.40 2.94E-02 
IPI00183695 S100A10 3.24 (± 0.68) 4.73 (± 0.79) 0.68 2.80E-02 
IPI00027463 S100A6 1.27 (± 0.20) 1.86 (± 0.32) 0.68 1.97E-02 
IPI00872909 NOP2 3.27 (± 0.36) 6.61 (± 0.19) 0.50 3.36E-06 
IPI00021805 MGST1 2.10 (± 0.43) 4.49 (±0.20) 0.47 5.71E-05 
IPI00921996 STMN1 0.47 (± 0.15) 10.86 (± 0.88) 0.04 4.09E-07 
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Since statistically significant quantitation by SWATH MS depended on peptide 
abundance related to baseline expression in each cell line, quantitative data was not 
always available from both E1 and HCT116 cell lines (Table 3-5). Nonetheless, 
these data from SWATHTM further increased the confidence of iTRAQTM quantitation 
in combination with other validation methods. This is crucial since the proteomics 








As shown in this section, iTRAQTM is a sensitive and highly quantitative tool for 
proteome profiling that provides breadth with extensive proteome coverage and 
depth with sensitivity. Instead of relying on a working hypothesis, the iTRAQTM 
approach is unbiased, and thus provides a global assessment of changes in protein 
expression.  
 
Based on iTRAQTM analysis of STMN1 KD cells, three main observations become 
evident. STMN1 silencing appears to simultaneously modulate (I) metastatic balance, 
(II) cell junctions and intracellular architecture, and (III) apoptotic defense. STMN1 
level may thus be regarded as a probable metastatic switch, since numerous 
expression changes in STMN1 KD cells reduce metastatic efficiency. 
 
The changes in metastatic balance concur with the loss of in vitro metastatic 
phenotype, as observed in Section 3.2, but strengthened cell junctions and reduced 
apoptotic defense remain to be validated functionally. In the next two sections, these 
changes are further investigated by confocal microscopy (Section 3.4) and 
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3.4 STMN1 silencing enhances cellular anchorage and 
intracellular rigidity  
 
 
iTRAQTM analysis of STMN1 KD cells detected expression changes in proteins that 
make up cell junctions and determine cellular fluidity. This section presents data that 
visually confirm the strengthening of hemidesmosomal junctions and intermediate 
filament (IF) tethering to desmosomes.  
 
  




In agreement with iTRAQTM data presented in Section 3.3.3, significantly stronger 
fluorescence signal corresponding to ITGA6 (red), ITGB4 (green) and LAMA5 
(magenta) were observed by three-colour confocal microscopy. In addition, 
increased ITGA6/ITGB4/LAMA5 co-localisation (white) indicate stronger 
hemidesmosomal linkages between neighbouring cells (Figure 3-16).  
 
 
Figure 3-16: STMN1 silencing strengthens hemidesmosomes. Up-regulation 
and co-localisation of ITGB4/ITGA6/LAMA5 in E1 STMN1 KD cells. Horizontal bar 
indicates 50 µm. Representative image (n=3). Similar data was obtained in 
HCT116 STMN1 KD cells. Antibody information, dilutions and detailed parameters 
used are found in Section 6.5.4. 
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3.4.2 Desmosomes and intermediate filaments  
 
Increased intensities of KRT1 (green), KRT9 (red) and DSP (magenta) in STMN1 KD 
cells were also observed (Figure 3-17), and found to be consistent with iTRAQTM 
data featured in Section 3.3.3. Increased KRT1/KRT9 co-localisation indicates higher 
complexity in intracellular architecture consisting of intermediate filament networks, 
while increased KRT1/KRT9/DSP co-localisation (white) suggests increased 
intermediate filament tethering to DSP plugs. 
 
 
Figure 3-17: STMN1 silencing increases intracellular rigidity. Up-regulation 
and co-localisation of KRT1/KRT9/DSP in E1 STMN1 KD cells. Horizontal bar 
indicates 50 µm. Representative image (n=3). Similar data was obtained in 
HCT116 STMN1 KD cells. Antibody information, dilutions and detailed parameters 
used are found in Section 6.5.4. 
  




This section demonstrated that STMN1 silencing not only cripples the metastatic 
machinery of CRC cells, but also inhibits metastatic phenotype by promoting the 
expression and assembly of hemidesmosomal proteins (ITGA6/ITGB4/LAMA5) into 
contact points between cells. Increased cell-cell contact provides a possible 
mechanism for increased cell adhesion observed in Section 3.2.3, and serves as 
deterrence against detachment prior to metastatic dissemination.  
 
In addition, STMN1 silencing also increases the expression and association of KRT1 
and KRT 9 into intermediate filaments (IFs) that dock at DSP plugs in desmosomes. 
These intracellular tethering should significantly increase rigidity in the metastatic 
cancer cells and hence reduce cellular fluidity and metastatic efficiency. 
 
Thus, in addition to direct modulation on metastatic balance, STMN1 silencing also 
indirectly restricts metastatic processes by strengthening cellular anchorage and 
interfering with intracellular fluidity. 
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3.5 STMN1 silencing promotes 5-Fluorouracil sensitivity  
 
 
Based on findings from iTRAQTM, STMN1 KD appears to down-regulate cellular 
apoptotic defense which could in turn increase chemo-sensitivity. This section 
describes a series of experiments aimed at investigating amplification of chemo-
response and the mechanism of apoptotic sensitisation induced by STMN1 silencing. 
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3.5.1 General cytotoxicity  
 
As revealed by iTRAQTM, several proteins implicated in apoptotic response were 
surprisingly regulated by STMN1 silencing (Table 3-4). These expression changes 
allude to the possibility of chemo-sensitisation, where an imbalance in pro-apoptotic 
protein expression and anti-apoptotic defense may reduce cancer cell viability during 
treatment stress. 
 
Figure 3-18: STMN1 silencing promotes sensitivity to MT inhibitors and 5FU. 
Cells were treated in triplicates for 48 hours with EC50 concentrations of each 
cytotoxic agent. Data represented as mean ± S.E. (n=4). STMN1 silencing 
induces mild sensitization to MT inhibitors Paclitaxel and Vinblastine (* p<0.05), 
but stronger susceptibility to 5FU in both primary HCT116 and metastatic E1 cells 
(** p<0.01). Relative cell viability of 1.0 indicates no change in sensitivity to 
treatment and is marked by dotted line for reference. Detailed treatment 
parameters are found in Section 6.5.5. 
 
To test this hypothesis, stable STMN1 KD cells were subjected to microtubule 
inhibition (paclitaxel and vinblastine), genotoxic stress (etoposide), chemotherapy (5-
Fluorouracil, 5FU), metabolic regulation (butyrate) or oxidative stress (tert-butyl 
hydroperoxide, TBHP). Sensitivity of STMN1 KD cells to these treatments were 
determined by cell viability relative to scrambled control cells and plotted as mean 
viability ± S.E. (n=3). As shown in Figure 3-18, STMN1 KD cells were significantly 
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more sensitive to 5FU compared to scrambled control cells (** p<0.01). Mild 
sensitization of STMN1 KD cells to microtubule (MT) inhibitors paclitaxel and 
vinblastine was also observed. 
 
Since STMN1 silencing amplified cell death during MT inhibition or 5FU treatment, 
the effect of these cytotoxic stress on STMN1 protein level was investigated in a 
time-dependent manner. Wild type HCT116 and E1 cells were treated with EC50 
concentrations of vinblastine (0.8 nM) and 5FU (12.5 nM) and harvested at 0, 2, 6, 8, 
24, 48 and 72 hours for western analysis. As shown in Figure 3-19, STMN1 protein 
level decreases after 6-8 hours of vinblastine treatment (A), while 5FU induced loss 




Figure 3-19: Microtubule inhibition and 5FU treatment decrease STMN1 level. Wild type 
HCT116 and E1 cells were treated with EC50 drug concentrations over  a 3-day time course. 
(A) Microtubule (MT) inhibition with Vinblastine reduced STMN1 level within 6-8 hours, while 
(B) 5-Fluorouracil (5FU) treatment reduced STMN1 level after 2 days. Representative western 
blot exposure (n=3). STMN1 was similarly down-regulated by Paclitaxel treatment within 6-8 
hours (data not shown). 
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3.5.2 5-Fluorouracil sensitisation  
 
Since the sensitising effect of STMN1 silencing to 5FU was unreported previously, 
and 5FU is a classical colorectal cancer chemotherapeutic agent in clinical use, the 
nature and mechanism for increased 5FU sensitivity in STMN1 KD cells were 
subsequently investigated (Sections 3.5.2 to 3.5.5). STMN1 KD and control cells 
were treated with 50, 100 or 150 µM 5FU for 48 hours and analysed by flow 
cytometry after propidium iodide staining. DMSO was used as a vehicle control.  
 
As shown in Figure 3-20, STMN1 silencing significantly increased cell death upon 
5FU treatment within the concentration window of 50 µM to 150 µM (** p<0.01). 
Enhanced cell death was of apoptotic nature given the presence of apoptotic nuclei 



















Figure 3-20: STMN1 silencing amplifies 5FU-dependent apoptosis. STMN1 
KD in E1 cells increases 5FU-induced apoptotic cell death between 50 and 150 
µM. FACS data for 50 and 100 µM 5FU treatments in triplicates showed 
significantly elevated apoptosis in STMN1 KD cells (** p<0.01). Data from one 
representative experiment shown as mean ± S.D. (n=4). Similar data was obtained 
in HCT116 STMN1 KD cells. Detailed treatment and measurement parameters are 
found in Sections 6.5.6. 
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3.5.3 Caspase-dependent apoptosis  
 
Since apoptotic cell death induced by 5FU treatment was enhanced after STMN1 
silencing, caspase involvement was next investigated in wild type HCT116 and E1 
cells using a panel of caspase inhibitors. It was necessary to identify the specific 
caspases that mediate 5FU induced apoptosis in wild type cells, since STMN1 KD 
cells could well target the same mechanisms to promote chemo-response. 
 
Wild type HCT116 and E1 cells were pre-treated with various caspase inhibitors 
before cell death was induced with 100 µM 5FU for 48 hours. As shown in Figure 3-
21, pre-treatment with caspase 3 or caspase 6 inhibitors partially restored cell 
viability after 5FU treatment (** p<0.01), suggesting that these caspases are 
responsible for 5FU-induced apoptotic cell death in CRC cells.  
 
Figure 3-21: 5FU-induced apoptosis is caspase-dependent. Inhibition of 
Caspase 6 and Caspase 3 strongly abrogated 5FU sensitivity in wild type HCT116 
and E1 cells (** p<0.01). DMSO is a solvent control in this experiment. Data 
represented as mean ± S.E. (n=3). Detailed treatment parameters are found in 
Section 6.5.7. 
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To test if chemo-sensitisation to 5FU in stable STMN1 KD cells was also mediated 
through caspase 3 and caspase 6, these caspases were similarly inhibited before 48 
hour treatment with 100 µM 5FU. As shown in Figure 3-22, inhibition of caspase 6 or 
caspase 3 indeed abrogated 5FU chemo-sensitising effect of STMN1 silencing (** 
p<0.01), further confirming that STMN1 KD amplified 5FU sensitivity through 
caspase 6 and probably its activation of caspase 3.  
 
 
Figure 3-22: 5FU sensitisation in STMN1 KD cells depends on Caspases 3 and 6. 
5FU induced apoptosis in E1 STMN1 KD cells, which was normalised by pre-treatment 
with inhibitors against Caspase 3 (C3I) (** p<0.01), Caspase 6 (C6I) (** p<0.01) or pan-
Caspase (CpanI) inhibitors (*** p<0.001). Data from one representative experiment 
shown as mean ± S.D. (n=4). DMSO is a vehicle control in this experiment. Similar 
data was obtained in HCT116 STMN1 KD cells. Detailed treatment and measurement 
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3.5.4 Caspase 6 activity  
 
Although inhibition of either caspase 6 or caspase 3 normalised 5FU sensitivity in 
STMN1 KD cells (Figure 3-22), iTRAQTM only detected expression differences in 
caspase 6 (Section 3.3.4).To confirm direct involvement of caspase 6 in STMN1 
silencing induced 5FU sensitisation, caspase 6 activity was measured in STMN1 KD 
and SC cells.  
 
Figure 3-23: Caspase 6 activity amplifies 5FU sensitivity. STMN1 silencing 
increases Caspase 6 activation upon 5FU treatment (**p<0.01), which was normalised 
by pre-treatment with C3I, C6I or CpanI. Data represented as mean ± S.E. (n=4). 
Detailed measurement parameters are found in Section 6.5.8. 
 
Caspase 6 activity was low in both STMN1 KD and SC cells at rest, but became 
significantly higher in STMN1 KD cells (** p<0.01) upon 5FU treatment (Figure 3-23), 
suggesting that STMN1 KD cells had a larger reserve of caspase 6 that could be 
readily activated upon 5FU trigger. When caspase 6 was inhibited, lower caspase 6 
activity observed was again consistent with reduced apoptotic cell death (Figure 3-
22). This further confirmed that STMN1 silencing improves 5FU sensitivity through 
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increasing expression of caspase 6, which amplifies apoptotic response when 
activated.  
 
Higher caspase 6 activity in STMN1 KD cells was also verified by western blotting 
where activated caspase 6 and cleavage of Lamin A were observable at lower dose 




Figure 3-24: Caspase 6 activation and cleavage of Lamin A. STMN1 silencing 
enhanced Caspase 6 activation and cleavage of Lamin A at 50 µM to 100 µM 5FU. 
Representative western blot (n=3). 
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3.5.5 Summary  
 
Summarising the data presented in this section, a model of STMN1 silencing 
induced 5FU sensitisation is proposed as follows (Figure 3-25). Treatment with 5FU 
reduces STMN1 expression and stabilises p53 to promote caspase 6 expression. 
STMN1 silencing on the other hand directly increases caspase 6 abundance via an 
alternative pathway, thereby providing a larger pool of caspase 6 that may be 
activated upon 5FU trigger.  This when coupled to increase in apoptotic potentiators 
and loss of apoptotic defense, further increases the potency of 5FU treatment. 
STMN1 silencing also reduces metastatic phenotype and tumour robustness, while 




Figure 3-25: Model of STMN1 silencing induced 5FU sensitisation. 
STMN1 silencing amplifies apoptotic response to 5FU treatment. Solid 
arrows indicate experimental findings, while dotted arrows represent 
direct evidence available in literature. Open arrows indicate up- or down-
regulations respectively. 
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3.6 STMN1 silencing regulates transcript abundance  
 
 
Proteome analysis of STMN1 KD cells provided a high-resolution, albeit ‘static’ 
snapshot of metastasis-related expression changes. To capture the ‘dynamic’ 
process of proteome regulation, the proteomics data was next complemented with 
extensive transcript analysis. This section details the targeted transcript 
measurement of 163 genes associated with tumour metastasis and epithelial-to-
mesenchymal transition (EMT) in stable STMN1 KD cells.  
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3.6.1 p38 phosphorylation  
 
Since progression of human CRC follows a dominant EMT programme117, the effect 
of STMN1 KD on mesenchymal transition and sustenance was investigated. As 
shown in Figure 3-26, the phosphorylation of p38, a well-known EMT marker118, was 
significantly blocked by STMN1 silencing. This observation suggests that 
mesenchymal changes may be inhibited in STMN1 KD cells, and that transcript 




Figure 3-26: p38 phosphorylation. STMN1 silencing inhibits p38 
phosphorylation while total p38 remains unchanged. Representative 
western blot (n=3). 
  













BLANK PAGE  
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3.6.2 Quality control  
 
To test if STMN1 silencing may also inhibit progressive acquisition of mesenchymal 
characteristics, the transcript levels of 163 genes associated with tumour metastasis 
and EMT were measured by quantitative real-time RT-PCR in STMN1 KD cells. Total 
RNA was extracted in duplicates from STMN1 KD and SC cells, and quantity and 
quality were determined as follows (Table 3-6).  
 
Table 3-6: RNA quality. Total RNA samples were extracted in duplicates from each cell line and 
quantified in triplicates. A260: A280 indicates RNA purity while A260: A230 detects the presence 
of contaminating chaotropic materials that may interfere with downstream applications. 
Sample Extraction 
Mean (n=3) 
A260: A280 A260: A230 Concentration (ng/µl) 
     
HKD 
A 1.926 2.182 248.8 
B 1.940 2.018 221.2 
     
HSC 
A 1.953 2.207 264.8 
B 1.954 2.208 237.6 
     
EKD 
A 1.938 2.156 161.2 
B 1.919 2.208 169.6 
     
ESC 
A 1.936 2.254 170.4 
B 1.938 2.191 174.4 
      
 
qPCR amplifications were performed in 384-well format in duplicates, and high 
reproducibility between replicates (r2 = 0.9906) was demonstrated in Figure 3-27. To 
further increase data confidence, quantitative information was only extracted when 
CT values are less than 30 in both replicates. Raw fold values for all differentially 
transcribed targets are found in Appendix III. 
  73   
 
 
Figure 3-27: qPCR reproducibility. A total of 682 out of 768 duplicate 
real-time RT-PCR reactions were amplified and CT values for array 
replicates 1 and 2 (R1 and R2) were highly reproducible overall 
(r2=0.9906; *** p<0.001). Quantitative information was extracted only 
when data points have CT ≤ 30 in both replicates.  
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3.6.3 CRC progression and cytoskeletal remodelling  
 
Stable STMN1 KD in both metastatic (E1) and primary (HCT116) CRC cell lines 
appear to inhibit CRC progression, by suppressing a core CRC oncogenic network 
consisting of MYC, MTA1, CXCR2, HPSE, METAP2 and CSTL1 (Figure 3-28). MYC 
is over-expressed in 70% of human CRC through β-catenin/TCF transcription119, 120, 
and inappropriate activation of MYC by Wnt/β-catenin is required for colorectal 
carcinogenesis121. In agreement with the positive regulatory effect of MYC on MTA1 
expression122, loss of MTA1 transcription was also observed together with MYC 
down-regulation (Figure 3-28).  
 
 
Figure 3-28: STMN1 KD inhibits CRC progression and cytoskeletal remodelling. 
Quantitative data from each replicate (R1 and R2) represented as log2 transformed 
fold change (KD:SC). 
 
MTA1 is another master regulator of CRC tumorigenesis123 that functions 
synergistically with MYC to promote angiogenesis through HIF-1α deacetylation and 
stabilization124. Loss of METAP2 was also likely a result of MYC suppression, since 
METAP2 transcription is similarly controlled by MYC122. METAP2 and CSTL1 are 
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known to control tissue invasion125 and basement membrane degradation126 
associated with tumour progression. Hence, the loss of oncogenic expression 
signatures as a result of STMN1 silencing may be largely mediated through MYC 
repression. 
 
The core CRC oncogenic network suppressed by STMN1 silencing also includes 
CXCR2, which supports inflammation-driven and spontaneous tumorigenesis as well 
as angiogenesis127. Loss of CXCR2 may also have contributed to 5FU sensitization 
observed experimentally (Section 3.5.2), since low CXCR2 was reported to promote 
chemo-sensitivity128. HPSE is a marker of poor CRC prognosis129 that was also 
down-regulated by STMN1 silencing. Taken together, STMN1 targeting could 
possibly counteract CRC progression mediated by these oncogenic drivers. 
 
Cytoskeletal remodeling was also evidently inhibited by STMN1 silencing, with 
significantly reduced expression of SET, AHNAK, STAT3 and RAC1 (Figure 3-28). 
Low AHNAK reportedly disrupts the formation of pseudopod protrusions130 and limits 
the availability of AHNAK scaffold necessary for RAC1 activation131. With low 
expression and activation of RAC1, key motile processes like cell polarization, 
lamellipodia formation132, and the stabilization of cell protrusions cannot be 
completed133. Moreover, the loss of SET expression should further cripple cell 
motility, since SET is required in RAC1-induced cell migration134. Lower STAT3 
expression induced by STMN1 silencing is also likely to reduce targeted motility, 
since STAT3 promotes directional migration through regulating the activity of 
RAC1135. Thus, STMN1 silencing-induced loss of cell migration observed previously 
is possibly a result of SET, AHNAK, STAT3 and RAC1 repression.  
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3.6.4 Metastatic and EMT transcriptional profile  
 
Stable STMN1 silencing significantly altered the transcript levels of numerous targets 
governing the acquisition of metastatic and mesenchymal properties (Figure 3-29). 
Stable inhibition of STMN1 expression consistently decreased the expression of 
proteins needed in motility, invasion and angiogenesis, including various MMPs136 
and TIMP2137 as well as SERPINE1138, ITGB3139 and PRL1140. TIMP3 on the other 
hand inhibits invasion141 and promotes apoptotic cell death142, and is up-regulated by 
STMN1 silencing, suggesting again the recurrent theme of tilting the balance in 
favour of metastatic inhibition and cell death. PNN serves to pin intermediate 
filaments to desmosomes143 and increase in PNN transcript abundance after STMN1 
silencing further supports the increase in desmosomal tethering and intracellular 
rigidity (Section 3.4). PNN up-regulation was also proposed to suppress neoplastic 
progression and increase adhesive properties in an apparent reversal of 
mesenchymal phenotype 144.  
 
STMN1 silencing also suppressed Wnt and TGFβ signaling (Figure 3-29) through 
decreasing the transcription of FZD7 receptor, as well as TGFB2, TGFB3, SMAD2 
and SMAD4. CRC carcinogenesis is known to involve molecular crosstalk of 
numerous signaling networks including that of Wnt and TGFβ145. Silencing of FZD7 
receptor was shown to suppress Wnt effects like c-Jun expression and JNK 
phosphorylation, thereby reducing tissue invasion and tumour progression146. TGFβ 
signaling on the other hand is known to promote metastasis of advanced cancers147, 
in particular colon cancer with microsatellite instability148. Hence, changes in Wnt and 
TGFβ pathways after STMN1 silencing suggest possible suppression of 
experimental metastasis72 through a complex myriad of signaling modulation. Indeed, 
the loss of SERPINE1 expression  is also a downstream effect of abrogated TGFβ 
signal relay149, with low expression of SMADs.  
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Figure 3-29: STMN1 KD reverses metastatic and EMT transcriptional profile. 
Data from each replicate (R1 and R2) represented as log2 transformed fold change 
(KD:SC). 
 
Following stable STMN1 silencing, markers of good cancer prognosis like EPHB2150, 
SYK151 and KISS1152 were also increased (Figure 3-29) while indicators of poor 
patient outcome JAG1153 and PTK2154 were reduced, suggesting again a general 
reversal of cancer progression. The expression of CTBP1, which interacts with Bcl3 
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to inhibit apoptosis, was also reduced, further supporting the notion of apoptotic 
sensitization after STMN1 silencing (Section 3.5). 
 
STMN1 silencing also induced a profound loss of EMT markers and transcription 
factors. CDH1 transcripts were significantly up-regulated, accompanied by the loss 
of mesenchymal marker VIM (Figure 3-29), while a large group of EMT transcription 
factors were also decreased. These include SNAI2, SNAI3, TCF4, ZEB1 and ZEB2, 
which have direct affinity for CDH1 promoter, as well as TWIST1, FOXC2 and GSC 
which regulate CDH1 expression indirectly155. A large majority of these EMT 
transcription factors are also implicated in CRC156, 157. The strong inhibition on CD44 
expression also supports the loss of matrix invasion158 after STMN1 KD, and likely 
prevents the direct reprogramming of CRC cells159. These transcript changes 
following stable STMN1 silencing strongly indicate a reversal of EMT phenotype, 
especially in the metastatic E1 cell line.  
 
In another liver-specific metastatic CRC cell line SW1116-M, EphB2 expression was 
reportedly lost while MMP3 and 9 transcripts were elevated160. In this work, STMN1 
silencing in metastatic CRC cell line E1 also reversed the levels of MMP3, 9 and 
EphB2 (Figure 3-29), further suggesting that loss of STMN1 may reverse metastatic 
and EMT changes in CRC in general.  
 
  




Increased expression of CDH1, TIMP3 and PNN, and down-regulation of MYC, 
MTA1, STAT3, MMP2, MMP9, SERPINE1, SMAD2 and SMAD4 at the protein level 
were validated by western blotting (Figure 3-30). Protein levels of STAT3 and CD44 
were also validated by label-free SWATH-MS in the E1 STMN1 KD cell line with 
higher baseline expression (Table 3-5, Section 3.3.5). 
 
 
Figure 3-30: qPCR validation by western blotting. Cell pellet was 
harvested parallel to total RNA extraction and lysed for western 








Summarising the data presented in this section, STMN1 silencing appears to impose 
master control over key oncogenic and metastatic processes. These include 
regulating the transcription of a large number of oncogenes and targets supporting 
cytoskeletal remodelling, as well as epithelial and mesenchymal drivers, such that a 
general reversal of EMT was apparent. These observations heavily implicate STMN1 
as a key node in the complex regulation of CRC progression. These extensive 
network modulations effected through targeting a single molecule clearly suggest the 
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3.7 Regulation of STMN1 function  
 
 
In previous sections, the role of STMN1 in metastatic processes was investigated in 
HCT116 and E1 cells. Lower STMN1 expression was associated with loss of 
metastatic potential, strengthening of cell-cell contact, as well as improvement in 
chemo-response. In this section, the regulation of STMN1 function is further 
investigated through mapping its interactions, understanding triggers for STMN1 
expression, and defining the role of specific STMN1 phosphorylations.   
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3.7.1 STMN1 interactions 
 
In search of STMN1-interacting proteins, co-immunoprecipitation (IP) was performed 
from total cell lysate using anti-STMN1 antibodies chemically coupled to protein A/G 
beads. Chemical coupling prevents the co-elution of antibody heavy and light chains 
by low pH. As shown in Figure 3-31, STMN1 IP visibly enriched for STMN1 in the 
eluate. 
 
Figure 3-31: STMN1 is enriched by immuno-
precipitation. STMN1 was enriched by immuno-
precipitation (IP) from 1 mg total cell lysate incubated 
overnight with STMN1 antibodies chemically coupled to 
protein A/G sepharose beads. Each lane was loaded with 




Combined eluates from eight STMN1 or control IP experiments were analysed by 
two-dimensional electrophoresis and visualised by silver staining against a 
proportional load of total cell lysate (Figure 3-32). Unique protein spots of sufficient 
intensity in IP:STMN1 eluate were identified by mass spectrometry. In Figure 3-32, 
STMN1 protein species are indicated by dotted rectangle, while the presence of 
RhoGAP8 in the eluate is indicated by dotted oval. Potential STMN1-RhoGAP8 
interaction was validated by probing for RhoGAP8 in IP:STMN1 eluate (Figure 3-33). 
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Figure 3-32: 2D separation of STMN1 IP eluate. STMN1 IP and control IgG 
eluates were resolved by two-dimensional (2D) electrophoresis and visualised 
by silver staining. 2D map of total cell lysate served as additional control to rule 
out non-specific interactions from proteins with high abundance. Dotted 
rectangle indicates the position of STMN1. Dotted oval indicates the position 
of RhoGAP8 identified by in-gel trypsin digestion and MS/MS analysis. 
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Figure 3-33: STMN1 potentially interacts with RhoGAP8. 
RhoGAP8 co-immunoprecipitates with STMN1 from both 
HCT116 and E1 total cell lysates. Representative western 
blot exposure (n=3). 
 
RhoGAP8 is a putative GTPase activating protein that “switches off” GTPase 
signaling required for cell motility. STMN1 interaction with RhoGAP8 may potentially 
remove RhoGAP8 from GTPase regulation and prolong the effect of motility 
signaling, thereby promoting cell migration (Figure 3-34). Further confirmation by 
reciprocal IP was however not conducted, since no commercial antibody suitable for 
IP was available. 
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Figure 3-34: STMN1 may regulate G protein signaling. GTPase 
activating proteins (GAPs) “switch off” GTPases by catalysing the 
conversion of bound GTP to GDP. GDP-bound form of GTPase is then 
inactive until a Guanine nucleotide exchange factor (GEF) replaces the 
GTP. STMN1 potentially interacts with RhoGAP8 to remove it from 
GTPase regulation, thereby prolonging the effect of GTPase signaling for 
motility. Diagram modified based on figure from Kiyokawa E, et al. 2011, 
Annu. Rev. Pharmaco. Toxicol. 51:337-58. 
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3.7.2 Fibronectin stimulation 
 
Fibronectin functions as a chemo-attractant to stimulate directional cell motility. To 
test if STMN1 expression is changed by fibronectin stimulation, cells were treated 
with fibronectin for 24 hours. As shown in Figure 3-35, presence of fibronectin 
promotes STMN1 expression within 24 hours, suggesting that STMN1 up-regulation 
may prime cells for motile processes. This is consistent with higher STMN1 
expression observed in the metastatic CRC cell line E1. Correspondingly, cells with 
higher baseline expression of STMN1 may thus respond even to a weak stimulus for 




Figure 3-35: Fibronectin induces STMN1 expression. 
Presence of 1  µg/ml fibronectin in culture medium induces 
STMN1 expression in 24 hours. 
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3.7.3 p53 dependence  
 
There exists an intricate link between STMN1 and p53. p53 is a known 
transcriptional repressor of STMN1161, thus STMN1 up-regulation with CRC 
progression could also mirror the progressive loss of p53. In addition, STMN1 
silencing also significantly perturbed the p53 transcriptional network based on 
iTRAQTM data (Figure 3-36).  
 
Figure 3-36: STMN1 silencing perturbs p53 transcirptional network. A list 
of iTRAQ targets regulated by STMN1 silencing mapped to p53 transcriptional 
network as the top hit. Diagram generated by IngenuityTM Pathway Analysis 
(IPA) web resource. Using notation standardised by IPA, differentially 
regulated proteins identified by iTRAQ are shaded, and different shapes 
represent different proteins classes (horizontal oval for transcription regulator; 
square for cytokine; inverted triangle for phosphatase; vertical oval for 
transmembrane receptor, horizontal diamond for peptidase; vertical 
diamond for enzyme). Solid arrows indicate direct evidence, while dashed 
arrows represent evidence inferred from literature. Proteins that reportedly 
interact are linked by solid lines. 
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 To further investigate if loss of p53 affects the efficacy of STMN1 silencing, STMN1 
KD was performed in HCT116 p53-/- cells (Figure 3-37).  
 
Figure 3-37: Stable STMN1 silencing in HCT116 p53-/- cells. 
Cells were treated with low dose of 5FU (10 µM) for 6 hours to 
induce p53 accumulation. 
 
 
Figure 3-38: Functional p53 not required to achieve efficacy of STMN1 
silencing. Stable STMN1 silencing in HCT116 p53-/- cells similarly 
abrogated cell migration and matrix invasion as in wild type (WT) HCT116 
cells (*** p<0.001). Data normalised against SC control and represented as 
mean fold change ± S.E. (n=3). 
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As shown in Figure 3-38, STMN1 KD inhibited migration (A-B) and invasion (C-D) 
even in the absence of p53, suggesting that functional p53 is not required for 
metastatic inhibition through STMN1 silencing. This potentially extends the utility of 
STMN1-based therapy to p53 null CRCs. 
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3.7.4 STMN1 phosphorylation 
 
In addition to expression differences, STMN1 may also be modified post-
translationally by phosphorylations at S16, S25, S38 or S63. To determine if STMN1 
function is regulated by specific or cumulative phosphorylations, point mutants 
harbouring S→A residue changes were generated by site-directed mutagenesis.  
 
Figure 3-39: STMN1 is phosphorylated at S16, 25, 38 and 63 in CRC cells. 
Transfected STMN1-DDK exists as a train of three spots (white arrows) on 2D 
maps that is typical of phophorylative modification(s). Single serine to alanine 
mutants when transfected show partial loss of phosphorylation (two spots), while 
quadruple alanine mutant STMN1 exists as a single spot without phosphorylation. 
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As shown in Figure 3-39, wild type HCT116 and E1 cells constitute full biological 
systems to process transiently transfected STMN1-DDK, resulting in a train of 
STMN1 spots typical of phosphorylative modification. The addition of phosphate 
groups reduces the iso-electric point (pI), thereby causing a left-ward shift in 2D 
maps. This explains the presence of multiple STMN1 spots at the same molecular 
weight but with differences in pI. 
 
Single S→A mutants showed partial loss of phosphorylation (2 spots) compared to 
WT STMN1 sequence (3 spots). Quadruple S→A mutant on the other hand showed 
complete loss of phosphorylation, leaving 1 spot corresponding to unphosphorylated 
STMN1. These observations suggest that STMN1 protein in HCT116 and E1 cells 
may be phosphorylated at any of the four serine residues or in combinations.  
 
In addition, since mutation at all four serine residues completely collapses all the 
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3.7.5 S25/38 phosphorylation in metastatic processes  
 
To test if specific or cumulative STMN1 phosphorylations are critical for pro-
metastatic activity, stable STMN1 KD cells were transfected with single S →A or 
4Ala mutants (Figure 3-40), to assay for rescue of transwell migration and matrigel 
invasion (Figure 3-41).  
 
Figure 3-40: Rescue of STMN1 KD by phosphorylation defective mutants. Stable STMN1 
KD cells were transiently transfected with single and quadruple alanine mutants for 48 hours. 
 
As shown in Figure 3-41, transient transfection of S25A or S38A STMN1 mutants 
failed to reconstitute transwell migration and matrigel invasion in STMN1 KD cells (** 
p<0.01), suggesting that STMN1 phosphorylation on S25 or S38 is crucial for pro-
metastatic activity. Inhibition of all serine phosphorylations on the other hand had no 
cumulative effect on metastatic phenotype, since transfection of 4Ala mutant 
produced similar effects as S→A mutants at either S25 or S38 (Figure 3-41). 
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Figure 3-41: STMN1 pro-metastatic activity depends on S25/38 
phosphorylation. Stable E1 STMN1 KD cells with inhibited migration and 
invasion were rescued with transient transfection of WT STMN1, S16A or S63A, 
but not with S25A, S38A or 4Ala mutants (** p<0.01). Data normalised against 
untransfected control (UT) and represented as mean fold change ± S.E. (n=3). 
Fold change in migration or invasion of 1.0 indicates a lack of rescue and is 
marked by dotted line for reference. Similar data was obtained in stable HCT116 
STMN1 KD cells. 
 
  




In this section, the mechanism of STMN1-dependent metastatic process was further 
investigated with respect to STMN1 induction, interaction and regulation of STMN1 
activity. Chemo-attraction by fibronectin was found to be a trigger for STMN1 
expression prior to directional motility, which may be supported by its interaction with 
RhoGAP8. STMN1-induced cell movement and invasion are in turn regulated by 
specific phosphorylative modifications on STMN1 at S25 or S38. These observations 
allude to complex and multi-layer control over STMN1 activity, and highlight the 
challenges in dissecting the STMN1 mechanism. 
 
The implications of these regulatory mechanisms are further discussed in the next 
section, with particular focus on CRC metastatic prevention. 
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4.1 Experimental strategy 
 
Metastatic transition in colorectal cancer is extremely complex, since extensive 
changes in protein expression and signaling crosstalk are required to support the 
acquisition of metastatic niche. To fully interrogate the intricacies of metastatic 
initiation and sustenance, a comprehensive workflow encompassing proteomics 
discovery, functional validation, transcript analysis and molecular verification was 
adopted.  
 
Proteome analysis of STMN1 KD cells was highly descriptive and provided a high-
resolution, albeit static snapshot of metastasis-related expression changes. This 
yielded fresh molecular insight into the mechanism of STMN1 silencing induced 
metastatic inhibition. Analysis of transcripts on the other hand served to complement 
proteomics data by describing the mechanism of proteome regulation through 
targeted measurement of the metastatic drivers implicated.  
 
Moreover, proteomics also provided a good starting point for molecular 
investigations, since new hypotheses may be formulated based on the expression 
changes detected. Herein, the decision to investigate Caspase 6 dependent chemo-
sensitisation after STMN1 silencing was strongly influenced by proteomics data. This 
method generates working hypotheses that are neither limited by the imagination of 
the experimenter, nor biased towards extensively studied protein targets, but instead 
represents the most time efficient and cost effective way to raise a research question.  
 
Using this targeted molecular approach guided by hypothesis-free proteomics, we 
evaluated comprehensively the potential benefits of STMN1 silencing in CRC 
metastatic prevention.  
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4.2 STMN1 expression drives in vitro metastatic phenotype 
 
 
The efficiency of tumour dissemination depends not on one, but many metastatic 
processes that take place in a successive and highly cooperative manner. Loss of 
cellular adhesion at the primary tumour site, coupled with enhanced cell migration 
and invasion, should facilitate access of the primary cancer cells to systemic 
circulation for dissemination, while the ability to re-establish malignant colonies 
independent of basal membrane anchorage should determine success of 
colonization at the distant site.  Therefore, an increase in single metastatic 
processes (e.g. migration) is unlikely to result in higher metastatic efficiency unless 
subsequent processes (e.g. invasion or colony formation) are also enhanced. 
Consequently, a complete assessment of metastatic efficiency should involve 
quantitative measurements of all these metastatic processes separately. 
 
Even though these metastatic processes are vastly different, STMN1 expression is 
central to the regulation of these diverse adaptations. As shown in Section 3.2, 
STMN1 expression is essential for all metastatic processes measured in vitro, 
thereby providing further justifications to rationalise conserved STMN1 elevation in 
cancer and disease (Section 1.2.4). Since silencing STMN1 in the context of a 
metastatic cell line streamlined for dissemination was sufficient to inhibit migration, 
invasion, colony formation, and enhance adhesion, STMN1 potentially functions at 
the crossroads of multiple disseminative pathways. Conversely, over-expression of 
STMN1 in the weakly metastatic primary HCT116 cells was also sufficient to induce 
a full-blown metastatic phenotype affecting the same metastatic processes. These 
observations suggest again that STMN1 could potentially fulfil the role of a master 
regulator in CRC metastasis located strategically at the node of several CRC 
metastatic cascades.  
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Despite early reports suggesting a role for STMN1 in cell cycle progression (Section 
1.2.3), no statistically significant difference in proliferation was observed in this study 
(Section 3.2.5). Since cell cycle inhibition by STMN1 was not previously reported in 
colon cell systems, this could be organ or cell-type specific. Based on immuno-
histochemical staining of normal colonic tissues (Figure 2-2, Section 2.1.1), STMN1 
expression is extremely low in normal colon cells. It is thus also possible that STMN1 
may be less involved in the regulation of intestinal cell cycle progression. 
Nevertheless, the lack of change in proliferative potential further suggested that 
STMN1 had specific functions in modulating CRC metastatic processes, and greatly 
simplified the procedure for other cell-based assays. 
 
Since STMN1 potentially mediates a wide range of signaling events in CRC 
metastatic progression, conventional experimental approaches dealing with single 
gene/protein measurements are indeed not suitable for investigating STMN1 function. 
Instead, a combined strategy involving proteome profiling and transcript 
measurements proved to be more appropriate to fully capture the involvement of 
STMN1 in CRC metastatic regulation.  
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4.3 Molecular benefits of STMN1 silencing 
 
 
In this series of investigations, STMN1 silencing appears to inhibit CRC metastatic 
processes by reinstating the default cellular programme of metastatic inhibition. This 
is achieved through re-induction of a large number of metastatic inhibitors often lost 
with tumour progression, together with the simultaneous suppression on metastatic 
protein expression.  
 
Subsets of these expression changes translate into altered cell surface composition 
and stronger basal-lateral anchorage, as well as reduced intracellular fluidity and 
hindered cytoskeletal remodeling, which directly impact detachment processes and 
morphological plasticity required for metastasis. These anti-metastatic expression 
changes observed after STMN1 silencing are also highly reflective of repressed 
oncogenic signaling, further highlighting the complexity of STMN1 dependent 
metastatic regulation.  
 
In addition, the molecular benefits of STMN1 silencing in CRC also include chemo-
sensitisation, where 5FU gains significant potency against metastatic cells via a 
novel caspase 6 dependent mechanism. Metastatic CRCs usually respond weakly to 
5FU-based chemotherapy but STMN1 silencing apparently tilts the balance in favour 
of apoptotic events by weakening apoptotic defense while simultaneously reducing 
the capacity to detoxify. Such observations further suggest the utility of STMN1 
silencing in the context of CRC metastatic prevention and therapy.  
 
At the global level, STMN1 silencing also appears to ameliorate CRC metastatic 
progression by suppressing oncogenic expression signatures and reversing EMT 
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transcriptional profiles. These changes indicate better CRC prognosis, but more 
importantly highlight the far-reaching impact of potential STMN1-based cancer 
therapy, since almost all the oncogenic and EMT transcription factors modulated by 
STMN1 silencing further control downstream amplification of other metastasis-
related genes. This is contrary to the belief that STMN1 functions only at the 
receiving end of signal transduction, but instead suggests a surprisingly pervasive 
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The benefits of STMN1 silencing, however, cannot be explained by structural 
features in the STMN1 sequence. Other than a prominent tubulin-interacting alpha-
helical region (Figure 4-1), no other functional domains allude to the mechanism of 
proteome regulation.  
 
Figure 4-1: Structure of STMN1 protein (schematic). Alpha-helical 
structure of central tubulin-interacting domain was determined 
experimentally45. 
 
Current knowledge of STMN1 function is mostly associated with regulation of mitotic 
spindle assembly. Since STMN1 sequesters dimeric tubulin162, it is a direct 
modulator of microtubule (MT) dynamics and anaphase chromosomal segregation56. 
Even so, the pro-metastatic activities of STMN1 documented in this work are unlikely 
to depend on MT regulation, since cell division should preclude locomotive or 
invasive processes to ensure fidelity of chromosomal division. In agreement with this, 
S63A does not affect metastatic phenotype despite its central location in the tubulin-
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interacting helical region (Figure 4-1). This further suggests that MT regulation and 
metastatic events are likely to be discrete functions of STMN1 at different times.  
 
On the contrary, STMN1 is more likely to function in metastatic processes through 
interactions with other proteins. In this respect, the N-terminal structure could 
determine affinity and accessibility of STMN1 interactions, since the majority of 
phosphorylation sites reside in the N-terminus. It was also suggested that N-terminal 
STMN1 may be intrinsically unstructured, and the molecule could depend on 
phosphorylation-induced conformation changes for activation163.  
 
In agreement with this proposed model, S25A and 38A mutants are not pro-
metastatic (Figure 3-40), further suggesting that key interactions required to initiate 
metastatic processes may indeed be precluded in the absence of phosphorylation-
induced conformation changes in the N-terminal regulatory region. This implies that 
apart from STMN1 silencing, inhibiting STMN1 phosphorylation at S25/38 may also 
prevent metastatic initiation.  
 
To date, vast majority of investigations into STMN1 phosphorylation and activity fail 
to address functional differences that may exist between differently phosphorylated 
species of STMN151, 164, 165. This work, on the other hand, demonstrates that different 
phosphorylations on four available serine residues further distinguish STMN1 
function, and that specific S25/38 phosphorylations on STMN1 critically enable pro-
metastatic activity. This imposes an additional layer of control in the regulation of 
STMN1 function, where metastatic initiation is concerned. 
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4.5 STMN1 silencing regulates metastatic networks 
 
 
Although the molecular effects of STMN1 silencing described above are diverse, 
tipping the balance remains a recurrent theme summarising the changes observed. 
STMN1 silencing appears to offset the balance between (i) metastatic activators and 
suppressors, (ii) apoptotic potentiators and inhibitors, as well as (iii) mesenchymal 
and epithelial maintenance, such that metastatic inhibition is favoured, and chemo-
response improved. These network changes suggest that STMN1 silencing 
regulates CRC progression at the systems level, rather than controlling single 
pathways.  
 
For instance, instead of relying on one dominant mechanism to inhibit EMT, STMN1 
silencing relays the signal to maintain epithelial phenotype through multiple 
pathways that converge at promoting CDH1 transcription. Increased E-cadherin 
expression was achieved in three ways: (i) down-regulating mesenchymal factors 
that repress CDH1 (SNAI2, SNAI3, ZEB1, FOXC2, GSC, TWIST1, TCF4)166, (ii) 
reducing the expression of STAT3167 and CTBP1168 that inhibit CDH1 transcription, 
as well as (iii) up-regulating PNN, which interacts with CTBP1 to further relieve 
CTBP1-mediated repression on CDH1 promoter169.  
 
In the regulation of epithelial phenotype described above, STMN1 silencing targets 
not only CDH1 transcription and repression, but also protein-protein interactions that 
promote CDH1 expression. Such a multi-foci mechanism of action could probably 
also be more robust in clinical application, since patients present with different 
disease etiology, as well as activating or inhibitory mutations.  
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4.6 STMN1 silencing: a potential therapy against metastatic CRC 
 
 
In summary of the data presented, STMN1 silencing appears to be a plausible form 
of therapy against CRC metastasis, in addition to its clinical significance in CRC 
prognosis72. Tumour dissemination arises when metastatic processes become more 
efficient, and chemotherapy fails to eliminate malignant cells in circulation. STMN1 
silencing targets both of these problems by inhibiting metastatic processes and 
simultaneously amplifying chemo-response. The mechanism of action depends not 
on MT regulation but on phosphorylative changes that potentially alter functional 
interactions, and consequently oncogenic signaling and mesenchymal transition 
(Figure 4-2).  
 
Unlike conventional targeted therapy, blocking STMN1 expression alters not only 
one signaling pathway, but relies on a multi-foci regulatory network to re-define the 
balance in metastatic signaling and cell survival. Given the increasing recognition 
that metastatic regulation must involve network perturbations and compensatory 
effects on top of linear signal relay, the potential for STMN1 silencing based CRC 









Figure 4-2: Model of STMN1 inhibition in CRC. STMN1 silencing inhibits cell migration, matrix invasion, CRC oncogenesis and progression, as well as EMT changes, while 
simultaneously promoting cell death sensitization and adhesion/cellular anchorage. Targets up-regulated and down-regulated by STMN1 silencing are indicated in red and blue 
respectively. Inhibition of STMN1 phosphorylation on S25 or S38 blocks cell migration and matrix invasion. Hence, inhibition of STMN1 expression or S25/38 phosphorylation 
may prevent CRC metastasis and associated mortality. 
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Even though STMN1 silencing tweaks global expressions, these effects are highly 
specific to metastatic response or chemo-resistance, and condensed into alteration 
of only 3% of the detectable proteome (Table 3-1). This further indicates that STMN1 
silencing possibly blocks CRC metastatic machinery specifically, with low off-target 
effects and minimal collateral damage. STMN1 expression in the normal colon is 
also extremely low, suggesting that high STMN1 level is not a pre-requisite to 
maintain normal colonic function, and that non-cancerous parts of the colon would be 
less affected by STMN1 depletion compared to cancerous lesions. Moreover, the 
efficacy of STMN1 silencing should also be minimally affected by loss of p53 that 
accompanies CRC progression, since p53 activity is not required in this novel 
mechanism. Collectively, these considerations further strengthen the feasibility of 
STMN1 silencing in CRC metastatic inhibition. 
 
Nevertheless, this potential anti-metastatic regime is still relatively distant from 
clinical application without animal testing. The next phase of investigations should 
thus involve validating the efficacy of STMN1 silencing in vivo. The comprehensive in 
vitro data presented here serves as crucial justifications for the use of animals in 
subsequent investigations.  
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5 Chapter 5 Conclusion and future work 
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Despite gradual decline in CRC incidence, metastatic spread remains a prominent 
cause of death in the world. Currently, metastatic complications are not preventable 
due to lack of prognostic monitoring, poor understanding of disseminative cascades, 
and shortage of potential inhibitory targets, while metastatic CRCs that have spread 
to distant organs are not effectively treatable due to low chemo-sensitivity. In view of 
these bottlenecks limiting further reduction in CRC mortality, this project was 
conceived to investigate the role of STMN1 in CRC metastasis and chemo-response. 
 
Elevated STMN1 expression was found to be indicative of CRC metastatic 
progression, and predictive of poor disease-free survival. Mechanistically, high 
STMN1 expression is sufficient to initiate metastatic processes in vitro, through 
promoting metastatic protein expression, as well as modulating oncogenic and 
mesenchymal transcriptional changes. Silencing of STMN1 on the other hand 
significantly improved sensitivity to existing 5FU chemotherapy through a novel 
caspase 6-dependent mechanism. STMN1 function in metastatic processes was 
further regulated at the expression level by chemo-attractant stimulation, at the 
interaction level through potential binding to RhoGAP8, and by phosphorylations at 
S25 or S38, which in turn have profound consequences on migratory and invasive 
processes. In addition to these findings, the power of an approach coupling 
proteomics and transcript analysis was demonstrated in a global assessment of 
treatment benefits and potential side-effects. 
 
With completion of these investigations, the experimental aims proposed in Section 
2.1.2 have been fulfilled. These findings further strengthen the framework to 
investigate STMN1 function in vivo, and in relation to phosphorylative modifications 
and cell cycle involvement.  
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The next phase of investigations should involve validating the loss of tumorigenicity 
in vivo of STMN1 KD cells, as well as generating S→ E activating mutations at 
S25/38 to confirm the involvement of these modifications in metastatic processes. 
Characterisation of STMN1 S25/38 phosphorylations should also involve identifying 
the upstream kinases, as well as testing if the phosphorylation-induced pro-
metastatic phenotype may be mitigated by PP2A phophatase activity. Since motile 
processes should be de-coupled from mitotic spindle regulation, distinct patterns of 
phosphorylation at single-residue resolution should also be pursued to better 
distinguish STMN1 function during normal cell division and processes of malignant 
spread. Differences in interaction partners during interphase and specific stages of 
the cell cycle should also be identified to carefully segregate normal STMN1 function 
from metastatic signaling. 
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6.1 Cell lines and constructs  
 
6.1.1 HCT116 and E1 cell lines  
 
The HCT116 human colon carcinoma cell line was obtained from ATCC (CCL-247TM). 
The liver-specific metastatic cell line E1 was obtained through collaboration with 
Professor Hooi Shing Chuan (Department of Physiology, NUS). This metastatic cell 
line was derived from liver-specific metastases formed in nude mice after repeated 
intra-splenic injection of HCT116 cells81. The HCT116 p53-/- cell line was a generous 
gift from Dr. Bert Vogelstein170 made available through Prof Hooi.  
All HCT116 and E1 cells lines were maintained in McCoy’s 5A medium (Sigma-
aldrich, MO, USA) supplemented with 10% fetal bovine serum (FBS) (Life 
Technologies, CA, USA). The culture media for stable knockdown (KD) and over-
expression (OE) cell lines were further supplemented with puromycin (Sigma-aldrich) 
or G418 (A. G. Scientific, CA, USA) to concentrations 1.0 µg/ml and 400 µg/ml 
respectively. 
 
6.1.2 Preparation of whole cell lysate 
 
Adherent cells were detached by trypsin and washed twice with ice-cold PBS. Cell 
pellets were lysed in 7 M Urea, 2 M thiourea, 4% CHAPS, 10 mM Tris supplemented 
with 1X HALT protease inhibitor cocktail (Thermo scientific), 50 µg/ml DNase I 
(Roche Diagnostic, Mannheim, Germany) and 50 µg/ml RNase A (Roche) by gentle 
vortexing. The lysate was cleared by centrifugation at 17,000xg for 1 hour, and 
supernatant was retained for estimation of protein content and further analysis. 
Protein estimation was performed using Coomassie Plus protein assay reagent kit 
(Thermo scientific) based on BSA standard curve.  
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6.1.3 STMN1 KD and OE constructs  
 
STMN1 silencing was performed using a commercial STMN1 shRNA (29-mer) vector 
selectable by Chloramphenicol (34 µg/ml) in E. Coli (pRFP-shSTMN1-C-RS; Origene, 
MD, USA). The shRNA sequence was GAATACACTGCCTGTCGCTTGTCTTCTAT 
and  targets a sequence in the STMN1 3’-UTR. STMN1 over-expression was 
performed with commercial over-expression vector (pCMV6-STMN1; Origene) 
selectable by Kanamycin (25 µg/ml) in E. coli. The over-expression cassette 
contained a full-length STMN1 sequence double tagged at the C-terminus with 
Myc/DDK. The empty pCMV6 vector control was generated by SalI/XhoI restriction 
digest and re-ligation. The same vectors were used for both transient and stable 





STMN1 S16A, S25A, S38A and S63A mutants were generated by site-directed 
mutagenesis (Stratagene, CA, USA) using pCMV6-STMN1 as template and 
mismatch primers as follows: 
 
Mutation Original sequence Mutagenesis primer 
S16A TCA 5' -- G-GAG-AAG-CGT-GCC-GCA-GGC-CAG-GC -- 3' 
S25A AG 5' -- GCT-TTT-GAG-CTG-ATT-CTC-C GC
S38A 
C-CCT-CGG-TCA-AAA-GAA-TC -- 3' 
TCC 5' -- CCA-GAA-TTC-CCC-CTT-GCC-CCT-CCA-AAG-AAG -- 3' 
S63A TCC 5' -- GAA-GAA-AGA-CGC-AAG-GCC-CAT-GAA-GCT-GAG-G --3' 
 
Table 6-1: Mutagenesis primers. 
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The primers used were 24-38 nucleotides long, had Tm ≥ 79oC as calculated by 
81.5+0.41(%GC)-675/N-(%MM), contained > 50% G+C and had no predictable 
secondary structure. PCR with mutagenesis primers was performed as follows: (1) 
95oC for 30s; (2) 16 cycles of 95 oC for 30s, 55 oC  for 1min, 68 oC for 6min; (3) 4 oC 
for 5min. Products of mutagenesis PCR were treated with Dpn I enzyme before 
transformation into XL1-Blue supercompetent cells (Stratagene). Colonies containing 
mutant STMN1 constructs were amplified and plasmid extracts were sequenced 
before transfection.  
 
Quadruple alanine mutant (S16A, S25A, S38A, S63A) was obtained commercially 
(Genscript, NJ, USA) and subcloned into pCMV6 mammalian expression vector 




For stable transfections, cells were seeded in 6-well format and allowed to reach 90% 
confluency in 48 hours. Plasmid DNA (0.8 µg) was first mixed with Lipofectamine 
2000 (Life Technologies) in serum-free medium before being added to each well. 
Fresh culture medium was replaced after 6 hours, and cells were re-plated at 1:20 
dilution 24 hours post transfection. Selections with puromycin (1.0 µg/ml) or G418 
(400 µg/ml) were then performed for 3 weeks until distinct colonies amplified from 
single transfected cells were visible to the naked eye. STMN1 knockdown or over-
expression was periodically monitored by western blotting with anti-STMN1 and anti-
DDK antibodies. For transient rescue of STMN1 KD, cells were seeded in 6-well 
format and allowed to reach 40% confluency in 24 hours. Transfections were 
performed similarly as above, but cells were only used for transwell migration and 
matrigel invasion assays 48 hours post transfection.   
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Cell doubling after STMN1 KD or OE was measured in 96-well format by crystal 
violet staining and dissolution in 1% SDS. Specifically, cells were seeded in 4 sets of 
7 replicates each at 10% confluency, and allowed to attach overnight. At 0, 24, 48 
and 72 hours, one set of cells was harvested by staining with 0.5% crystal violet (w/v) 
(Sigma) in 20% methanol (v/v) for 10 min. Cell doubling was quantified by intensity at 
500nm of crystal violet dissolved in 1% SDS, and normalised at each time point to 0 
hour. Cell proliferation was plotted based on 3 independent experiments as mean 
fold change ± S.E. in Figure 3-10. 
 
6.2.2 Wound healing 
 
The ability to close a wound gap was measured using a twin-chamber migration 
insert (Ibidi, Munich, Germany) in 24-well format. Cells were seeded at > 95% 
confluency in both chambers, and allowed to adhere overnight in full medium. To 
initiate wound healing, the silicon insert was removed with sterile foreceps and the 
wells were washed with serum free medium. Cells were then maintained in serum 
free conditions until the 500 µm gap between the two chambers was completely 
closed. Ability to heal a wound gap was rated qualitatively by visual assessment. The 
experiment was repeated 3 times and representative images are shown in Figure 3-5. 
 
Figure 6-1: Wound healing insert. Image modified from insert product specifications (ibidi). 
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6.2.3 Transwell migration 
 
Efficiency of cell migration was measured using 8.0 µm transwell migration inserts 
(Becton-Dickinson, CA, USA) in 24-well format. The underside of transwell inserts 
were coated with 1 µg/ml Fibronectin (Sigma) at 4oC for 16 hours, and rinsed twice 
with PBS before 5x104 cells were seeded in medium containing 1% FBS. The outer 
chamber was filled with full medium containing 10% FBS and 1 µg/ml Fibronectin to 
set up chemo-attractant gradient. Cells were allowed 48 hours to migrate through the 
pores of the PET membrane to the underside of the transwell insert.  
 
Figure 6-2: Transwell migration insert. 
 
After 48 hours, cells that remained in the inner chamber of the insert were removed 
by gentle scrubbing, while cells that have migrated across the membrane barrier 
were fixed with 3% paraformaldehyde (w/v) and stained with 0.5% crystal violet (w/v) 
in 20% methanol (v/v). Representative images are shown in Figure 3-6. To quantify 
differences in transwell migration, the crystal violet retained in cells was solubilised in 
1% SDS and absorbance at 595nm was normalised to control cell lines. Mean fold 
changes in transwell migration ± S.E. from 3 independent experiments was plotted in 
Figure 3-6 and Figure 3-41. 
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6.2.4 Matrigel invasion 
 
Efficiency of matrix invasion was measured using 8.0 µm BioCoatTM MatrigelTM 
invasion chambers (Becton-Dickinson, CA, USA) in 24-well format. The inserts were 
re-hydrated in serum-free medium for 2 hours at 37oC and washed twice with warm 
serum-free medium before 1x105 cells were seeded in medium containing 1% FBS. 
The outer chamber was filled with full medium containing 10% FBS to set up chemo-
attractant gradient. Cells were allowed 2.5 days to invade through the matrigel layer 
to the underside of the invasion insert.  
 
Figure 6-3: Matrigel invasion chamber. 
 
To visualize and quantify cell invasion, cells were fixed and stained as described in 
Section 6.2.3. Representative images are shown in Figure 3-7. The experiment was 
repeated at least 3 times and fold change in matrigel invasion was plotted as mean 
fold change ± S.E. in Figure 3-7 and Figure 3-41. 
 
6.2.5 Cell adhesion 
 
Cellular adhesive properties were measured by an adhesion assay in triplicates in 
96-well format. Wells were coated with 1 µg/ml Fibronectin at 4oC for 16 hours and 
rinsed twice with wash buffer (culture medium supplemented with 0.1% BSA). 
Blocking was performed with 0.5% BSA in culture medium at 37oC for 1 hour. Wells 
were then washed twice again and chilled on ice. Subsequently, 4x104 cells were 
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seeded per well and allowed to adhere for 40 minutes at 37oC. Adherent cells were 
fixed and stained with crystal violet as detailed in section Section 6.2.3. Five 
representative images were taken per well across triplicates and the attached cells 
were summed. The assay was performed at least 3 times, and the mean number of 
attached cells ± S.E. was plotted in Figure 3-8. 
 
6.2.6 Anchorage-independent colony formation 
 
The ability to form anchorage-independent colonies was measured by soft agar 
assays in quadruplicates in 24-well format. The top agar consisted of cell suspension 
in 0.4% agarose while the bottom agar contained 0.6% agarose. Five thousand cells 
were seeded per well and fed with full medium supplemented with puromycin or 
G418 every three days for a duration of 4 weeks. Colonies formed were stained with 
0.005% (w/v) crystal violet in 20% methanol overnight and subsequently de-stained 
with 20% methanol. Twenty representative images per taken per well across 
quadruplicates, and the total number of colonies ± S.E. was plotted in Figure 3-9. 
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6.3 Proteome profiling  
 
6.3.1 iTRAQTM: labeling chemistry 
 
Isobaric Tags for Relative and Absolute Quantitation (iTRAQTM) are a set of stable 
isotope labels that react with peptide amine groups. In 8-plex iTRAQTM, eight 
available labels each contain a peptide-reactive group, a reporter group of mass 
between 113 to 121 Da, and a balance group. Different reporter ion masses are 
achieved only by varying isotopic composition while maintaining the isobaric tag 
mass at 305 Da (Figure 6-4).  
 
Figure 6-4: iTRAQ labels. Image adopted from  iTRAQ product specifications (AB SCIEX). 
 
Due to isobaric nature of the tags, the MS spectrum of the labelled peptide mixture 
resembles the spectrum of individual samples. Upon collision induced dissociation 
(CID), the peptide-linked tags fragment to release the reporter ions for quantitation 
(Figure 6-5), while the peptide sequence indicates protein identity. With eight 
isobaric tags, iTRAQTM labeling thus allows the simultaneous quantitation of up to 
eight different biological samples in one LC/MS run.  




Figure 6-5: iTRAQ reporter ions. Image adopted from  iTRAQ product specifications (AB SCIEX). 
 
When coupled to a reproducible LC system and a sensitive mass spectrometer, the 
iTRAQTM methodology is highly robust and suitable for comparison of global protein 
expression. In this work, such a workflow was applied to profile the changes in total 
proteome upon STMN1 silencing in both primary and metastatic CRC cells. 
 
6.3.2 iTRAQTM: sample preparation 
 
 
Figure 6-6: iTRAQ sample pooling. iTRAQ pooling and isobaric tagging strategy (schematic). 
Biological triplicates (passages 8-10; P8-10) were pooled by protein amount, reduced and alkylated for 
protein digestion, and resulting peptides were labeled with isobaric tags for relative quantitation. 
 
Total proteome profiling was performed using an 8-plex iTRAQTM labeling strategy. 
Cell lysates from E1 and HCT116 STMN1 KD cells (EKD; HKD) were analysed 
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quantitatively alongside the respective scrambled control cell lines (ESC; HSC). 
Three biological replicates of each cell line (P8-P10) were lysed in 8M Urea, 25mM 
TEAB, 2% Triton X-100, 0.1% SDS171 supplemented with 1X HALT protease inhibitor 
cocktail (Thermo scientific), 50 µg/ml DNase I (Roche Diagnostic, Mannheim, 
Germany) and 50 µg/ml RNase A (Roche), and pooled by protein amount to reduce 
biological variation (Figure 6-6).  
 
Figure 6-7: iTRAQ experimental workflow. 
 
A 50 µg sample of each pooled lysate was reduced with tris-(2-carboxyethyl) 
phosphine (TCEP), alkylated with methyl methane-thiosulfonate (MMTS), and diluted 
1:10 with 0.5 M TEAB (triethylammonium bicarconate) before digestion with trypsin 
(Applied Biosystems, CA, USA). Digested peptides were dried and labeled with 
isobaric tags (EKD: 113; ESC: 114; HKD:117; HSC:118) according to product 
specifications (AB SCIEX, MA, USA). Labeled peptides were combined and Strong 
Cation Exchange (SCX) was performed to remove excess iTRAQ reagents, trypsin 
and detergents. The eluted fraction from SCX was desalted using Sep-Pak tC18 
cartridge (Waters, MA, USA), dried and reconstituted in 95% H2O, 5% acetonitrile 
(ACN), 0.1% Formic acid (FA) for 2D LC-MS/MS analysis (Figure 6-7).  
 
6.3.3 iTRAQTM: 2D LC-MS/MS  
 
Peptide separation was first performed using a strong cation-exchange (SCX) 
column on the Ultimate LC system (Dionex-LC-Packings, CA, USA). A total of 72 µg 
of labeled peptide mixture was loaded by multiple injection via micro-pickup loop 
mode into a Zorbax Bio-SCX II column (Agilent, CA, USA). The mobile phase used 
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at a flow rate of 10 µl/min were: (A) 5% acetonitrile (ACN) with 0.05% formic acid 
(FA); (B) 5% ACN, 500mM NaCl with 0.05% FA. A total of 18 fractions were 
collected using step gradients of mobile B as follows: 0% for 10 min; 0-20% for the 
next 90 min; followed by 20-60% for 20min; 60-100% for another 10 min; before 
holding at 100% for the last 25 min. Each fraction was then desalted with Sep-Pak® 
tC18 µElution plate (Waters, MA, USA) using vacuum manifold.  
In the second dimension, each SCX fraction was further separated by reverse phase 
(RP) chromatography using columns packed with Reprosil-Pur C18-AQ 3 µm 120Å 
phase (Eksigent, CA, USA). Each fraction was first trapped on a precolumn (200 µm 
x 0.5 mm), and then eluted on an analytical column (75 µm x 150 mm) for separation. 
The RP mobile phase used were: (A) 98% H2O, 2% ACN with 0.1% FA; (B) 98% 
ACN, 2% H2O with 0.1% FA. Step gradients of mobile B were used at a flow rate of 
300 nl/min and are as follows: 5% for 1 min; 5-12% for the next 2 min; followed by 
12-30% for 120 min; before holding at 90% for the last 5 min. 
Information Dependent MS analysis was performed using  TripleTOF® 5600 analyser 
(AB SCIEX), where precursor ions (mass range 400-1800 m/z) were selected using 
250ms accumulation time per spectrum. Up to 20 precursors from each MS 
spectrum were selected for MS/MS analyses, where tandem MS was recorded, with 
rolling collision energy and iTRAQ reagent collision energy adjustment, in high 
sensitivity mode. 
 
6.3.4 iTRAQTM: protein and peptide identification 
 
Protein identification and relative iTRAQ quantification was performed with the 
ProteinPilotTM software 4.2 (AB SCIEX) using the ParagonTM algorithm for peptide 
identification. Search parameters were defined as:(1) sample type: iTRAQ 8-plex 
(peptide labeled); (2) cysteine alkylation: MMTS; (3) digestion: trypsin; (4) instrument: 
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TripleTOF 5600; (5) species: Homo sapiens; (6) ID focus: biological modifications; (7) 
database: ipi.HUMAN.v3.87.fasta (182888 proteins searched); (8) search effort: 
thorough; (9) FDR analysis: yes; (10) user modified parameter files: no. Auto bias 
correction was applied, and peak areas were extracted from the database using 
Protein Pilot for relative quantitation. False discovery rate (FDR) in peptide 
identification was estimated using a reverse database search strategy. 
 
6.3.5 iTRAQTM: data analysis 
 
Quantitative expression changes were obtained by comparison of iTRAQTM reporter 
intensities. Relative protein abundance in STMN1 KD cells compared to control cells 
was determined by the reporter ratios EKD:ESC (113:114) and HKD:HSC (117:118) 
respectively. Based on experimental cut-off ratios determined previously, proteins 
with iTRAQ ratios >1.3 or <0.769 were considered significantly up- or down-
regulated respectively.  
 
Figure 6-8: iTRAQ threshold filtering. 
 
Sequential filtering was performed by restricting the dataset to proteins that were (i) 
consistently regulated by STMN1 silencing in both E1 and HCT116 cells, and (ii) 
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curated and shown to exist at the protein level. Functional annotation (Figure 3-11) 
was based on well-characterised molecular function documented in at least 2 
independent publications extracted from extensive literature review. Targets 
differentially regulated by STMN1 silencing in both E1 and HCT116 cells are 
tabulated in Appendix I. Top transcription network was predicted with IngenuityTM 
Pathway Analysis (Qiagen, Hilden, Germany). 
 
6.3.6 SWATHTM MS: label-free technology 
 
Sequential Window Acquisition of all TH
 
eoretical Mass Spectra (SWATHTM MS) is an 
emerging technology that enables label-free quantitation at the proteome level172. 
MS/MSALL with SWATH™ Acquisition is a data-independent acquisition method that 
generates a permanent digital record of all possible ions in a single MS/MS analysis, 
to enable retrospective and iterative re-mining without re-acquisition. This is 
achieved by sequential fragmentation of all ions across chromatographic time, and 
high-speed scanning across mass windows with high resolution and mass accuracy 
(Figure 6-9). Quantitation is performed by calculation of MS/MS peak area. 
Figure 6-9: SWATH acquisition. Figure modified from SWATH MS/MSALL technical note (AB SCIEX). 
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Although SWATHTM MS is also a quantitative LC-MS/MS approach like iTRAQTM, no 
peptide labelling is required. This further eliminates potential bias introduced by 
additional preparative procedures.  SWATHTM MS is thus a parallel method suitable 
for verification of iTRAQ data. In this work, SWATHTM MS was used to validate 
proteome changes induced by STMN1 silencing. 
 
6.3.7 SWATHTM MS: sample preparation and analysis 
 
Label-free peptide-based validation of expression changes was performed using a 
quantitative SWATH workflow. Specifically, 30 µg total protein from each cell line 
(consecutive passage; P11) was digested, processed by SCX and desalted in a 
manner similar to iTRAQ sample preparation but without isobaric tagging, and 
reconstituted in 98% H2O, 2% ACN, 0.1% FA for SWATH analysis.  
Peptide equivalents from 1.2 µg sample were analysed in quadruplicates on the 
TripleTOF® 5600 analyser (AB SCIEX) in SWATH MS mode. The RP mobile phase 
used were: (A) 98% H2O, 2% ACN with 0.1% FA; (B) 98% ACN, 2% H2O with 0.1% 
FA. Step gradients of mobile B were used as follows: 5% for 1 min; 5-10% for the 
next 9 min; 10-25% for 70 min; followed by 25-40% for 15min; 40-90% for 10min; 
before holding at 90% for the last 15 min. Each SWATH MS/MS acquisition was 
performed between 100-1800 Da using collision energy of 35V with a spread of 15V. 
At a cycle time of 3 s, 50 ms TOF/MS survey scan was performed between 350-1250 
Da with 45x20 Da acquisition windows, and 65ms accumulation time. Protein 
identification was performed based on an ion library generated separately as 
described in Section 6.3.8.. 
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6.3.8 SWATHTM MS: protein identification and quantitation 
 
To generate ion library, EKD, ESC, HKD and HSC peptides were mixed in equal 
proportions and analysed by an Information Dependent Acquisition (IDA) LC-MS/MS 
method with cycle time of 2.8s, consisting of a high-resolution TOF/MS survey scan 
of 350-1800 m/x mass range for 250ms accumulation time, followed by MS/MS 
analyses of up to 25 selected precursors with intensity greater than 125cps.  
Charged state for MS/MS ranged between 2 to 5, and each MS/MS acquisition was 
performed in high sensitivity mode and rolling collision energy for 100ms with a scan 
of 100-1800 Da. Dynamic exclusion for 22s was performed.  
Protein identification was performed using ProteinPilot software version 4.5 against 
the Swissprot database. Peak alignment and ion library matching was performed 
using PeakView software version 1.2 (AB SCIEX). Quantitation was performed by 
comparing peak area of EKD and HKD samples against ESC and HSC controls 
across replicates. Peak area calculation and statistical analyses were performed 
using MarkerView software version 1.2.1 (AB SCIEX).  
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6.4 Transcript analysis  
 
6.4.1 RNA extraction and quantification 
 
Cells were seeded in duplicates in 6-well format and allowed 48 hours to reach 70% 
confluency. Total RNA was then extracted using RNeasy ® Plus mini spin columns 
(QIAGEN, Hilden, Germany) with gDNA elimination, and quantified at room 
temperature with Nanovue spectrophotometer (GE Healthcare, CT, USA) by the 
mean of triplicate readings. All RNA extracts have A260:A230 ratios > 2.0, A260:A280 
ratios > 1.9, and concentrations exceeding 160 ng/µl in RNase-free water. 
 
6.4.2 qPCR array 
 
Reverse transcription was performed using RT2 First Strand Kit (QIAGEN) according 
to product specifications. Duplicate total RNA extracts were first pooled  by RNA 
content, after which 400 ng of each pooled sample was used to generate cDNA 
template for duplicate real-time qPCR amplification of 163 genes implicated in 
epithelial-to-mesenchymal transition (EMT) and metastasis (QIAGEN). 
SYBR Green signal was recorded in 384-well PCR array format on the ViiA7TM Real-
Time PCR system (Applied Biosystems), with ramp rate set to 1oC/s. Baseline and 
threshold cycle (CT) were determined in linear and log view respectively using the 
ViiA7TM software. Relative quantitation was performed against beta Actin (ACTB) as 
the loading control, and only amplifications with CT < 30 were analysed. The 
experiment was repeated to obtain data from another biological replicate (Array set 
2), where reproducibility was verified (Figure 3-27). Data from qPCR experiments 
were represented using Multiple experiment Viewer173 (MeV) version 4.81 (Figure 3-
28 and Figure 3-29). 
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6.5 Molecular methods  
 
6.5.1 1D western blotting 
 
In western detection of target proteins, 20 µg total protein was resolved in 12.5% 
SDS-PAGE, and transferred by Trans-Blot Cell (Bio-Rad Laboratories) to PVDF 
membrane (Merck Millipore, MA, USA) using Towbin buffer (0.025M Tris, 0.192M 
Glycine, 20% Methanol). Membranes were blocked with 5% milk/TBS-T for 1 hour at 
room temperature, and probed with various antibodies in 1% milk/TBS-T as follows:  
Manufacturer Target Host Dilution 
    
Abcam                                       
(Cambridge, UK) 
STMN1 Rabbit monoclonal 1:10,000 
ADAM15 Rabbit monoclonal 1:1,000 
S100A6 Rabbit monoclonal 1:1,000 
S100A10 Rabbit monoclonal 1:1,000 
MGST1 Rabbit polyclonal 1:100 
Caspase 6 Rabbit monoclonal 1:1,000 
    
Santa Cruz                               
(TX, USA) 
PI-9 Mouse monoclonal 1:1,000 
p53 Rabbit polyclonal 1:3,000 
Lamin A Rabbit monoclonal 1:3,000 
Myc Rabbit polyclonal 1:500 
MTA1 Rabbit polyclonal 1:500 
STAT3 Rabbit polyclonal 1:500 
E-cadherin Mouse monoclonal 1:500 
MMP9 Rabbit monoclonal 1:300 
MMP2 Rabbit polyclonal 1:300 
SERPIN E1 Goat polyclonal 1:500 
Smad 2 Mouse monoclonal 1:500 
Smad 4 Mouse monoclonal 1:500 
Pinin Mouse monoclonal 1:500 
 RhoGAP8 Rabbit polyclonal 1:1000 
    
Cell Signaling                      
(MA, USA) 
p38 Rabbit polyclonal 1:500 
phospho-p38 Rabbit monoclonal 1:300 
    Origene            
(MD, USA) DDK Mouse monoclonal 1:1,000 
     
Table 6-2: Primary antibodies for western blotting. 
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Primary antibodies used at dilutions of 1:1,000 or more were incubated at room 
temperature for 2 hours. Weaker primary antibodies used at 1:100 to 1:500 were 
incubated overnight at 4oC. All secondary antibody incubations were performed for 1 
hour at room temperature, in 1% milk/TBS-T at dilutions indicated below: 
Manufacturer Antibody Dilution 
      
GE Healthcare 
(Uppsala, Sweden) Sheep anti-mouse 1:5,000 
      
Santa Cruz                  
(TX, USA) 
Goat anti-rabbit 1:10,000 
Donkey anti-goat 1:5,000 
      
 
Table 6-3: Secondary antibodies for western blotting. 
 
HRP signals were visualized using Super Signal West Dura substrate (Thermo 
scientific). Western exposures were captured on Kodak Biomax MR Film (Eastman 
Kodak Company, NY, USA), developed by SRX-101A Processing Machine (Konica 
Minolta, NJ, USA) and films were scanned with UMAX ImageScanner (GE-
healthcare, Uppsala, Sweden). When western detection of more than one protein 
was necessary on the same membrane, stripping was performed with RestoreTM 
PLUS western blot stripping buffer (Thermo Scientific) for 10 minutes. 
 
6.5.2 2D western blotting 
 
In 2D western blotting, proteins were separated first by charge then by molecular 
weight, before being transferred to PVDF membrane for western detection. In the 
first dimension, 18cm pH3-10 non-linear (NL) Immobilised pH Gradient (IPG) strips 
were rehydrated passively for 16 hours in 7 M urea, 2 M thiourea, 4% (w/v) CHAPS, 
20 mM dithiothreitol (DTT), 0.2% (w/v) IPG buffer and trace bromophenol blue, 
before 100 µg  total protein was introduced via cup loading. Isoelectric focusing was 
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performed by Ettan IPGphor II IEF unit (GE healthcare) as follows: (i) 300 V, 600 Vhr; 
(ii) 500 V, 250 Vhr: (iii) 1,000 V, 500 Vhr; (iv) 1,000-8,000 V, 12,000 Vhr; and (v) 
8,000V, 48,000 Vhr. For 7-cm IPG strips, 10 µg total protein was resolved with a 
correspondingly reduced focusing step at (v) 8,000V, 12,000Vhr. 
Before the second dimension, IPG strips were reduced with 1% (w/v) DTT and 
alkylated with 2.5% (w/v) iodoacetamide (IAA) for 15 min each, in 6 M urea, 30% (v/v) 
glycerol, 50 mM Tris-HCl (pH8.8), 2% (w/v) SDS and trace amounts of bromophenol 
blue. Second dimension was resolved in 12.5% SDS-PAGE, and western blotting 




Cells were lysed as described in section 6.1.2, but lysis buffer was additionally 
supplemented with 1X phosphatase inhibitor cocktail (Sigma-aldrich). For complete 
dephosphorylation, 100 µg total cell lysate was treated with 130 U of bovine 
intestinal alkaline phosphatase (Sigma-aldrich) in 200 µl reaction buffer (5 mM Tris-
HCl, 10 mM NaCl, 1 mM MgCl2, 0.1 mM DTT, pH7.9). Enzyme was omitted from the 
control reaction and replaced with reaction buffer, and dephosphorylation was 
performed at 37oC for 2 hours with gentle shaking.  
Dephosphorylated and control lysates were precipitated by 2D cleanup kit (GE 
healthcare), and resuspended in 15 µl rehydration buffer (7 M urea, 2 M thiourea, 4% 
(w/v) CHAPS, 20 mM DTT and 0.2% (w/v) IPG buffer). Two-dimensional 
electrophoresis and western blotting was performed using 18-cm pH3-10 non-linear 
(NL) Immobilised pH Gradient (IPG) strips and 12.5% SDS-PAGE gel as detailed in 
Section 6.5.2. 
 




For immuno-staining, cells were seeded in 4-well Lab-Tek II chamber slides (Thermo 
Scientific, MA, USA) and grown to 70% confluency in 1.5 days. Cells were fixed in 4% 
paraformaldehyde, permeabilised in 0.2% Triton/PBS-T and blocked with 0.3M 
Glycine in 1% BSA/PBS-T. Primary and secondary antibody incubations were 
performed with gentle shaking for 2 hours at room temperature. Antibodies used in 
imaging are as follows: 
Manufacturer Target Host Dilution 
        
Abcam                                       
(Cambridge, UK) 
STMN1 Rabbit monoclonal 1:400 
S100A10 Rabbit monoclonal 1:200 
        
Santa Cruz                               
(TX, USA) 
RACK1 Mouse monoclonal 1:200 
Hugl1 Mouse monoclonal 1:100 
PI-9 Mouse monoclonal 1:50 
ITGB4 Mouse monoclonal 1:100 
ITGA6 Rat monoclonal 1:100 
LAMA5 Rabbit polyclonal 1:200 
KRT1 Mouse monoclonal 1:50 
DSP Rabbit polyclonal 1:100 
        
Fitzgerald                      
(MA, USA) KRT9 Guinea pig polyclonal 1:50 
        
Life Technologies                               
(CA, USA) 
Alexa® 488 goat anti-mouse 1:400 
Alexa® 555 goat anti-rat 1:400 
Alexa® 555 goat anti-guinea pig 1:400 
Alexa® 633 goat anti-rabbit 1:400 
        
 
Table 6-4: Immuno-fluorescence antibodies. 
 
Double and triple staining were performed by mixing antibodies during primary as 
well as secondary antibody incubations. DAPI counter-stain was used at 300nM. All 
images were acquired by the LSM710 confocal microscopy system (Carl Zeiss, 
Oberkochen, Germany) and exported by the AxioVision Rel. 4.8 software. 





EC50 of cytotoxic agents Paclitaxel, Vinblastine, Etoposide, 5-Fluorouracil (5FU), 
Butyrate and Tert-butyl hydroperoxide (TBHP) were first estimated experimentally 
using wild type E1 and HCT116 cells. Cells were seeded in 96-well format in 7 
replicates and treated with varying concentrations of cytotoxic agents spanning 3 
orders of magnitude. EC50 was estimated from sigmoid curves of cell viability against 
log (dose). 
Cell death sensitization was tested by treating STMN1 KD cells in triplicate 6-well 
format with EC50 concentrations of cytotoxic agents: Paclitaxel (4 nM), Vinblastine 
(0.8 nM), Etoposide (20 µM), 5-FU (12.5 µM), Butyrate (1.5 mM) and Tert-butyl 
hydroperoxide (4 µM). Adherent cells at the end of 48-hour treatments were 
quantified by crystal violet staining and dissolution in 1% SDS. The experiment was 
repeated 4 times and the mean cell viability ± S.E. was plotted in Figure 3-18. A 
parallel set of cells were lysed as described in section 6.1.2 for western blotting to 
check for changes in STMN1 protein level (Figure 3-19). 
 
6.5.6 Flow cytometry 
 
STMN1 KD and control cells were treated in triplicates with 0, 50, 100 or 150 µM 
5FU in 6-well format for 48 hours to induce apoptotic cell death. Floating and 
adherent cells were combined, fixed with ice-cold 70% ethanol and fragmented DNA 
was extracted with 192mM Na2HPO4, 0.004% Triton X-100. Apoptotic nuclei were 
stained with 20 µg/ml Propidum Iodide (Sigma-aldrich) supplemented with 50 µg/ml 
RNase A (Sigma-aldrich), and analysed by FACS Aria flow cytometer analyzer 
(Becton Dickinson). Mean percentage apoptotic cells ± S.E. from 4 independent 
experiments was plotted in Figure 3-20. 
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6.5.7 Caspase inhibition 
 
Caspase inhibitors were reconstituted to concentrations of 20 mM in DMSO, and 
diluted 1:10 in full medium to obtain 2mM treatment media as working stocks. Wild 
type E1 and HCT116 cells were seeded at 10% confluency in 96-well triplicates and 
pre-treated with inhibitors against caspase 1, 2, 3, 4, 6, 8, 9, 10, 13 or pan-caspase 
inhibitors (R&D Systems, MN, USA) at 100 µM final concentration for 48 hours, 
before apoptosis was induced with 100 µM 5FU for another 48 hours also in the 
presence of caspase inhibitors. Cell viability was quantified by crystal violet staining 
and dissolution in 1% SDS, as described in Section 6.2.1. The experiment was 
repeated 3 times and the mean cell viability ± S.E. was plotted in Figure 3-21. 
To test if 5FU susceptibility in STMN1 KD cells was caspase-dependent, 
fluoromethyl ketone (fmk)-derivatised peptides (R&D Systems) that irreversibly block 
caspase 3 (Z-DEVD-FMK; C3I), caspase 6 (Z-VEID-FMK; C6I) or all caspases (Z-
VAD-FMK; CpanI) were used. Cells were similarly pre-treated with 100 µM inhibitors 
for 48 hours before induction of apoptosis with 5FU. The mean cell viability ± S.E. 
from 4 independent experiments was plotted in Figure 3-22. 
 
6.5.8 Caspase 6 activity 
 
STMN1 KD and SC cells were seeded in triplicates in 96-well format, and treated 
with 0, 50, 100 or 150 µM 5FU for 48 hours. Caspase 6 activity was measured by 
Caspase-Glo® 6 Assay (Promega, WI, USA) according to product specifications. 
Luminescence was recorded by Infinite M200 Luminescence Reader (Tecan, 
Switzerland) 1 hour after cell lysis. Mean luminescence signal ± S.E. from 4 
independent experiments was plotted in Figure 3-23.  
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Activation of caspase 6 and consequent cleavage of caspase 6 substrate Lamin A 
was verified by western blotting (Figure 3-24) using a parallel set of cells treated in 6-
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6.6 Data representation  
 
6.6.1 Graphs and data visualisation 
 
All graphs were plotted by GraphPad Prism software version 5.00 for Windows (CA, 
USA). Data from qPCR experiments were represented using Multiple experiment 




Cultured cells and cell-based assays were visualised under Nikon Eclipse TS100 
microscope (Nikon, Tokyo, Japan), and digital images were acquired by Nikon 
Coolpix 4500 camera in JPEG format. Western exposures on film were scanned by 
UMAX ImageScanner (GE-healthcare) and exported in TIFF format. Immune-
fluorescence images were acquired by the LSM710 confocal microscopy system 
(Carl Zeiss) and exported by the AxioVision Rel. 4.8 software in TIFF format. 
 
6.6.3 Statistical analyses 
 
All statistical analyses were performed by GraphPad Prism software version 5.00 for 
Windows. Two-sample t-test with equal variance was used in all experiments, with 
the exception of caspase inhibition, where paired t-test was used instead. 
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117:118   
(HKD: HSC) 
IPI00019359 44.1 KRT9 Keratin, type I cytoskeletal 9 15 36.31 1.46 
IPI00220327 63.2 KRT1 Keratin, type II cytoskeletal 1 32 11.17 1.45 
IPI00007249 27.4 ENPP4 Ectonucleotide pyrophosphatase/phosphodiesterase family member 4 3 3.60 1.43 
IPI00298057 64.1 PPL Periplakin 30 3.53 1.53 
IPI00027264 51.7 CALB2 Calretinin 6 3.28 2.21 
IPI00969145 13 ADAM15 Isoform 6 of Disintegrin and metalloproteinase domain-containing protein 15 3 2.99 3.10 
IPI00023876 43.3 CASP6 Isoform Alpha of Caspase-6 4 2.70 2.36 
IPI00029468 58 ACTR1A Alpha-centractin 15 2.70 1.61 
IPI00299084 41.3 TMEM33 Transmembrane protein 33 6 2.51 1.43 
IPI00418426 25.3 CNNM4 Metal transporter CNNM4 3 2.40 1.33 
IPI00783625 73.9 SERPINB5 Isoform 1 of Serpin B5 18 2.38 1.56 
IPI00220194 28.5 SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 13 2.33 1.33 
IPI00795801 23 CD109 Isoform 4 of CD109 antigen 2 2.33 2.00 
IPI00027883 21.2 MAST1 Microtubule-associated serine/threonine-protein kinase 1 2 2.29 8.17 
IPI00654755 60.5 HBB Hemoglobin subunit beta 4 2.29 2.75 
IPI00220845 48 ITGB4 Isoform Beta-4A of Integrin beta-4 52 2.27 1.33 
IPI00007188 91.3 SLC25A5 ADP/ATP translocase 2 46 2.17 1.31 
IPI00017802 36.6 AUH Isoform 1 of Methylglutaconyl-CoA hydratase, mitochondrial 5 2.15 2.49 
IPI00301051 34.2 NHLRC2 Isoform 1 of NHL repeat-containing protein 2 10 2.09 1.53 
IPI00031608 37.1 SPATA5L1 Isoform 1 of Spermatogenesis-associated protein 5-like protein 1 6 2.07 1.72 
IPI00896467 21.7 ARHGEF10L Isoform 5 of Rho guanine nucleotide exchange factor 10-like protein 2 2.03 1.53 
IPI00940816 39.3 ARHGEF2 Isoform 3 of Rho guanine nucleotide exchange factor 2 15 2.01 1.32 
IPI00334282 77.1 FAM3C Protein FAM3C 15 1.98 1.34 
IPI00187011 37.5 ZC3H4 Zinc finger CCCH domain-containing protein 4 10 1.96 1.32 
IPI00296259 73.1 TMED4 Isoform 1 of Transmembrane emp24 domain-containing protein 4 13 1.92 1.32 
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IPI00099463 48.9 SGPL1 Sphingosine-1-phosphate lyase 1 11 1.87 1.31 
IPI00293613 29.1 TBK1 Serine/threonine-protein kinase TBK1 3 1.85 2.40 
IPI00607787 42.4 UAP1 Isoform 3 of UDP-N-acetylhexosamine pyrophosphorylase 7 1.80 1.77 
IPI00329664 30.4 SMURF2 E3 ubiquitin-protein ligase SMURF2 3 1.77 2.31 
IPI00418382 21.4 OPLAH 5-oxoprolinase 5 1.74 1.75 
IPI00232806 51.4 SMC2 Isoform 2 of Structural maintenance of chromosomes protein 2 7 1.72 1.37 
IPI00514055 50.5 GNAS Isoform Gnas-1 of Guanine nucleotide-binding protein G(s) subunit alpha  11 1.69 2.63 
IPI00295387 39.6 CRLF3 Cytokine receptor-like factor 3 2 1.67 1.85 
IPI00023101 51.5 RQCD1 Cell differentiation protein RCD1 homolog 4 1.66 1.43 
IPI00183530 47.9 SNX1 cDNA FLJ46302 fis, clone TESTI4036048, highly similar to Sorting nexin 1 7 1.66 3.25 
IPI00794129 29.4 DDHD1 Isoform 2 of Phospholipase DDHD1 3 1.66 1.80 
IPI00847550 31.9 PHF3 Isoform 2 of PHD finger protein 3 5 1.66 1.38 
IPI00155601 33.5 MACROD1 MACRO domain-containing protein 1 5 1.64 1.64 
IPI00854741 38.2 LLGL1 Lethal(2) giant larvae protein homolog 1 (Hugl1) 10 1.64 1.38 
IPI00152981 59.1 ACAD9 Acyl-CoA dehydrogenase family member 9, mitochondrial 12 1.61 1.60 
IPI00337741 53.6 APEH Acylamino-acid-releasing enzyme 18 1.61 1.54 
IPI00009456 37.1 NT5E 5'-nucleotidase 7 1.57 1.77 
IPI00018415 37.1 TM9SF2 Transmembrane 9 superfamily member 2 18 1.57 1.42 
IPI00022648 48.7 EIF5 Eukaryotic translation initiation factor 5 11 1.57 1.34 
IPI00010154 73.8 GDI1 Rab GDP dissociation inhibitor alpha 33 1.56 4.97 
IPI00304866 41.6 TNFAIP2 Tumor necrosis factor alpha-induced protein 2 3 1.56 1.36 
IPI00329236 38.3 PRKCD Protein kinase C delta type 2 1.56 2.56 
IPI00013933 64.6 DSP Isoform DPI of Desmoplakin 52 1.54 1.38 
IPI00019549 40 SMAD1 Mothers against decapentaplegic homolog 1 2 1.54 3.73 
IPI00023832 31.6 SH3PXD2B SH3 and PX domain-containing protein 2B 5 1.54 1.47 
IPI00798122 27.5 FNDC3B Isoform 2 of Fibronectin type III domain-containing protein 3B 2 1.54 1.53 
IPI00921080 43.5 ITGA6 Isoform 7 of Integrin alpha-6 11 1.54 1.31 
IPI00031169 85.9 RAB2A Ras-related protein Rab-2A 15 1.53 1.31 
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IPI00472416 48.3 HLA-B;HLA-C;HLA-A;MICA;LOC441528 HLA class I histocompatibility antigen 13 1.53 1.71 
IPI00176706 68.8 RBM17 Splicing factor 45 10 1.51 1.57 
IPI00299904 56.6 MCM7 Isoform 1 of DNA replication licensing factor MCM7 24 1.51 1.34 
IPI00022664 36.9 RABGGTA Geranylgeranyl transferase type-2 subunit alpha 6 1.50 1.56 
IPI00012585 46.6 HEXB Beta-hexosaminidase subunit beta 9 1.46 1.32 
IPI00291755 34.8 NUP210 Isoform 1 of Nuclear pore membrane glycoprotein 210 27 1.46 1.43 
IPI00009070 43.4 HBS1L Isoform 1 of HBS1-like protein 6 1.45 1.82 
IPI00149650 40.3 PPWD1 Peptidylprolyl isomerase domain and WD repeat-containing protein 1 3 1.43 1.32 
IPI00419802 56.5 HIBCH Isoform 1 of 3-hydroxyisobutyryl-CoA hydrolase, mitochondrial 10 1.43 2.00 
IPI00607784 40.9 ZNF638 Isoform 3 of Zinc finger protein 638 6 1.42 1.36 
IPI00305144 41.3 TSSC4 Isoform 1 of Protein TSSC4 (Fragment) 4 1.41 1.69 
IPI00028065 43.2 NCK1 Cytoplasmic protein NCK1 3 1.39 1.38 
IPI00299413 29.1 GABPA GA-binding protein alpha chain 6 1.39 1.36 
IPI00301323 56.1 DDX18 ATP-dependent RNA helicase DDX18 14 1.39 1.42 
IPI00783665 20.4 LAMA5 Laminin subunit alpha-5 4 1.38 1.87 
IPI00024024 48.5 AKAP17A Isoform 1 of A-kinase anchor protein 17A 2 1.37 1.33 
IPI00304267 47.1 NXN Isoform 1 of Nucleoredoxin 9 1.37 1.38 
IPI00016179 58.2 S100A13 Protein S100-A13 7 1.36 1.32 
IPI00023299 34.7 DDX12P Probable ATP-dependent RNA helicase DDX12 2 1.36 1.39 
IPI00291607 41.7 ITPR3 Inositol 1,4,5-trisphosphate receptor type 3 27 1.34 1.56 
IPI00291467 92 SLC25A6 ADP/ATP translocase 3 (ANT3) 36 1.33 1.66 
IPI00293748 35.3 MINPP1 Isoform 1 of Multiple inositol polyphosphate phosphatase 1 3 1.33 2.65 
IPI00218414 63.1 CA2 Carbonic anhydrase 2 13 1.32 1.61 
IPI00298625 57 LYN Isoform LYN A of Tyrosine-protein kinase Lyn 4 1.32 1.36 
IPI00002240 29.1 FAM118B Protein FAM118B 2 1.31 1.31 
IPI00012866 46.3 AKT1 RAC-alpha serine/threonine-protein kinase 5 1.31 1.46 
IPI00289454 42.3 MUS81 Crossover junction endonuclease MUS81 2 1.31 1.66 
IPI00895801 64.2 ACADM Isoform 2 of Medium-chain specific acyl-CoA dehydrogenase, mitochondrial 9 1.31 1.63 
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IPI00945818 40.7 LRBA Uncharacterized protein 23 1.31 1.77 
IPI00556308 18 GYG1 Isoform GN-1 of Glycogenin-1 2 0.77 0.54 
IPI00290460 37.8 EIF3G Eukaryotic translation initiation factor 3 subunit G 9 0.76 0.72 
IPI00031461 78.4 GDI2 cDNA FLJ60299, highly similar to Rab GDP dissociation inhibitor beta 51 0.75 0.75 
IPI00294891 55.8 NOP2 Isoform 1 of Putative ribosomal RNA methyltransferase NOP2 17 0.75 0.71 
IPI00376798 69.7 RPL11 Isoform 1 of 60S ribosomal protein L11 16 0.75 0.71 
IPI00384861 42.2 GIT1 Isoform 1 of ARF GTPase-activating protein GIT1 4 0.75 0.65 
IPI00026358 37.6 GABARAPL2 Gamma-aminobutyric acid receptor-associated protein-like 2 2 0.74 0.77 
IPI00007174 45.5 NAA20 N-alpha-acetyltransferase 20, NatB catalytic subunit 3 0.74 0.58 
IPI00396258 58.2 BCAT2 Isoform A of Branched-chain-amino-acid aminotransferase, mitochondrial 15 0.74 0.40 
IPI00336047 35.7 MYO9B Isoform Long of Myosin-IXb 6 0.73 0.52 
IPI00013917 88.6 RPS12 40S ribosomal protein S12 30 0.72 0.58 
IPI00477494 41.5 DRAP1 Uncharacterized protein 3 0.72 0.56 
IPI00032139 66.8 SERPINB9 Serpin B9 (PI-9) 16 0.72 0.62 
IPI00032561 56.3 CAB39 Calcium-binding protein 39 7 0.72 0.74 
IPI00008530 85.2 RPLP0 60S acidic ribosomal protein P0 39 0.71 0.72 
IPI00022403 61.2 MRPL13 39S ribosomal protein L13, mitochondrial 3 0.71 0.69 
IPI00024670 54 REEP5 Receptor expression-enhancing protein 5 3 0.70 0.51 
IPI00295400 74.5 WARS Isoform 1 of Tryptophanyl-tRNA synthetase, cytoplasmic 34 0.70 0.71 
IPI00008037 75.3 ACSL5 Isoform 1 of Long-chain-fatty-acid--CoA ligase 5 39 0.70 0.67 
IPI00848226 91.8 GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 (RACK1) 73 0.69 0.53 
IPI00017704 65.5 COTL1 Coactosin-like protein 11 0.68 0.54 
IPI00024417 50.2 HIP1R Huntingtin-interacting protein 1-related protein 11 0.68 0.64 
IPI00798400 54.2 EIF4G1 Isoform D of Eukaryotic translation initiation factor 4 gamma 1 51 0.68 0.67 
IPI00221093 71.9 RPS17;RPS17L 40S ribosomal protein S17 15 0.67 0.62 
IPI00305833 61.2 SMU1 WD40 repeat-containing protein SMU1 15 0.67 0.53 
IPI00150057 36.1 SMARCC2 Isoform 2 of SWI/SNF complex subunit SMARCC2 19 0.66 0.64 
IPI00479877 57.5 ALDH9A1 4-trimethylaminobutyraldehyde dehydrogenase 20 0.65 0.77 
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IPI00001159 53.2 GCN1L1 Translational activator GCN1 73 0.65 0.65 
IPI00021805 29 MGST1 Microsomal glutathione S-transferase 1 4 0.65 0.62 
IPI00009057 66 G3BP2 Isoform A of Ras GTPase-activating protein-binding protein 2 13 0.64 0.61 
IPI00181359 37 SCAF11 Isoform 2 of Protein SCAF11 2 0.63 0.72 
IPI00221091 90 RPS15A 40S ribosomal protein S15a 25 0.63 0.40 
IPI00000051 50 PFDN1 Prefoldin subunit 1 2 0.62 0.77 
IPI00017341 29.3 SF3A2 SF3A2 protein (Fragment) 5 0.62 0.62 
IPI00221092 82.9 RPS16 40S ribosomal protein S16 15 0.62 0.63 
IPI00022078 61.7 NDRG1 Protein NDRG1 30 0.61 0.62 
IPI00071318 58.8 LUC7L Isoform 1 of Putative RNA-binding protein Luc7-like 1 4 0.61 0.74 
IPI00010463 33 GTPBP1 GTP-binding protein 1 6 0.59 0.77 
IPI00739902 42.5 MIA3 Isoform 2 of Melanoma inhibitory activity protein 3 15 0.56 0.71 
IPI00011253 92.6 RPS3 40S ribosomal protein S3 42 0.55 0.73 
IPI00748403 29.4 INTS4 Isoform 3 of Integrator complex subunit 4 2 0.53 0.54 
IPI00090327 34.6 VPS45 Vacuolar protein sorting-associated protein 45 2 0.53 0.67 
IPI00026230 63 HNRNPH2 Heterogeneous nuclear ribonucleoprotein H2 27 0.52 0.70 
IPI00013877 64.5 HNRNPH3 Isoform 1 of Heterogeneous nuclear ribonucleoprotein H3 16 0.49 0.52 
IPI00183695 66 S100A10 Protein S100-A10 4 0.48 0.70 
IPI00186290 79.5 EEF2 Elongation factor 2 131 0.48 0.64 
IPI00794566 49.6 SLMAP Isoform 2 of Sarcolemmal membrane-associated protein 3 0.47 0.63 
IPI00102069 48.9 EIF3M Eukaryotic translation initiation factor 3 subunit M 17 0.45 0.74 
IPI00305545 42.1 DBR1 Isoform 1 of Lariat debranching enzyme 5 0.43 0.73 
IPI00554761 66 HMGN1P38;HMGN1 Non-histone chromosomal protein HMG-14 7 0.41 0.67 
IPI00007423 42.2 ANP32B Isoform 1 of Acidic leucine-rich nuclear phosphoprotein 32 family member B (APRIL) 23 0.39 0.62 
IPI00022254 35.4 ATG3 Isoform 1 of Ubiquitin-like-conjugating enzyme ATG3 6 0.36 0.70 
IPI00219718 72.6 RBP1 retinol-binding protein 1 isoform a 17 0.29 0.64 
IPI00742670 41.1 PON2 cDNA FLJ55597, highly similar to Serum paraoxonase/arylesterase 2 12 0.26 0.56 
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IPI00027463 83.3 S100A6 Protein S100-A6 17 0.25 0.77 
IPI00014266 31.7 BRD3 Isoform 1 of Bromodomain-containing protein 3 5 0.22 0.37 
IPI00479997 70.5 STMN1 Isoform 1 of Stathmin 7 0.05 0.05 
 
* Highlighted targets referenced in main text. 
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Data set Protein ID Target STMN1 KD Scrambled control KD/SC 
Run 1 Run 2 Run 3 Run 4 S.D. Run 1 Run 2 Run 3 Run 4 S.D. Fold change P-value 
                              
EKD-ESC 
IPI00220327 KRT1  134017 148924 130843 131927 8434 73633 77938 66643 63162 6677 1.94 1.8E-05 
IPI00291467 ANT3 272223 258128 262707 272109 7036 157753 153076 153948 148732 3703 1.74 1.3E-07 
IPI00783625 SERPINB5 68216 89652 102576 89125 14217 43103 58725 50876 49468 6418 1.73 3.2E-03 
IPI00019359 KRT9 7064 6222 5245 8947 1572 3502 5916 3129 3892 1244 1.67 3.3E-02 
IPI00220847 ITGB4  95303 91527 92689 87895 3076 52388 54455 48056 66702 7993 1.66 1.4E-04 
IPI00759824 APRIL 150255 152648 150358 150372 1161 217621 209004 202772 213779 6405 0.72 1.7E-06 
IPI00784414 STAT3 9909 13553 9956 11663 1727 16249 22889 22082 23819 3415 0.53 2.0E-03 
IPI00984539 CD44 104510 111757 116052 124158 8214 260175 260179 264906 254620 4206 0.44 6.7E-08 
IPI00921996 STMN1 20135 24634 33691 14944 7950 291558 291101 292741 281138 5376 0.08 2.3E-09 
                              
HKD-HSC  
IPI00921401 ITGA6 67243 67613 68659 68755 755 46916 37099 43132 34135 5775 1.69 7.6E-05 
IPI00783625 SERPINB5 59461 60315 51206 66774 6386 48545 35421 32796 53442 10009 1.40 2.9E-02 
IPI00183695 S100A10 35611 22769 32766 38301 6783 42404 42983 44926 59049 7880 0.68 2.8E-02 
IPI00027463 S100A6 12145 12723 10521 15259 1967 14127 20405 18518 21376 3214 0.68 2.0E-02 
IPI00872909 NOP2 37922 32391 30641 30010 3598 66715 63556 68228 66040 1947 0.50 3.4E-06 
IPI00021805 MGST1 18195 25763 16561 23443 4329 43841 47402 42833 45721 2026 0.47 5.7E-05 
IPI00921996 STMN1 3801 6727 4574 3505 1455 114685 95824 114150 109746 8801 0.04 4.1E-07 
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EKD ESC HKD HSC 
R1 R2 R1 R2 R1 R2 R1 R2 
                    
Figure  
3-28 
MYC -0.834 -0.783 0.046 -0.063 -1.132 -1.010 0.037 -0.037 
MTA1 -1.557 -1.665 0.001 -0.001 -0.546 -0.667 0.010 -0.010 
CXCR2 -0.297 -0.418 -0.045 0.097 -0.795 -1.431 0.011 -0.048 
HPSE -0.426 -0.314 0.067 -0.070 -0.371 -0.384 0.078 -0.062 
SET -0.530 -0.793 -0.070 0.067 -0.380 -0.355 0.017 -0.018 
AHNAK -0.435 -0.561 -0.020 0.020 -1.079 -0.616 -0.062 0.045 
STAT3 -0.542 -0.550 -0.063 0.061 -0.422 -0.386 0.021 -0.022 
RAC1 -0.492 -0.674 0.079 -0.084 -0.444 -0.527 -0.030 0.029 
METAP2 -2.073 -1.836 0.064 -0.067 -0.753 -0.789 -0.032 0.077 
CSTL1 -0.486 -0.353 -0.021 0.052 -0.319 -0.352 0.024 -0.024 
                    
Figure  
3-29 
JAG1 -0.519 -0.722 -0.022 0.021         
EPHB2 0.935 1.006 -0.014 0.014         
SYK 0.610 0.517 -0.029 0.029         
FZD7 -0.282 -0.385 0.002 -0.003         
TGFB2 -2.473 -2.156 -0.009 0.008         
SMAD2 -3.281 -2.987 0.030 -0.030         
SMAD4 -1.188 -0.937 -0.033 0.032         
MMP2 -0.318 -0.305 0.021 -0.022         
MMP3 -0.481 -0.315 -0.034 0.034         
MMP9 -0.340 -0.319 0.021 -0.022         
MMP10 -0.669 -0.687 0.024 -0.025         
MMP13 -0.737 -0.774 -0.052 0.050         
TIMP2 -0.872 -0.714 -0.015 0.015         
TIMP3 4.610 4.716 0.043 -0.044         
ETV4 -0.949 -1.178 -0.023 0.022         
CD44 -19.932 -19.932 -0.120 0.110         
PNN 1.664 1.583 -0.054 0.053         
SERPINE1 -19.932 -19.932 0.092 -0.098         
CTBP1 -0.762 -0.796 0.019 -0.019         
CDH1 0.521 0.462 0.031 -0.032         
VIM -2.241 -2.074 0.033 -0.033         
SNAI2 -1.311 -1.263 -0.050 0.048         
SNAI3 -0.417 -0.527 -0.054 0.052         
ZEB1 -1.257 -1.516 0.035 -0.036         
FOXC2 -0.296 -0.315 0.048 -0.050         
                    
Figure  
3-29 
KISS1         -0.674 -0.757 0.007 -0.007 
PTK2         0.578 0.577 0.028 -0.028 
FZD7         -0.706 -0.590 -0.055 0.053 
TGFB3         -0.267 -0.419 -0.024 0.023 
MMP7         -0.960 -1.166 0.081 -0.085 
MMP9         -0.555 -0.469 0.051 -0.052 
CTSK         -0.907 -0.756 -0.026 0.025 
CXCR4         -2.402 -2.083 0.038 -0.040 
FN         -1.207 -1.181 -0.061 0.058 
ITGB3         -2.953 -3.010 -0.030 0.030 
MTSS1         -1.281 -1.214 0.037 -0.038 
SRC         -0.611 -0.672 0.050 -0.052 
PRL1         -1.372 -1.267 0.025 -0.025 
CDH1         0.526 0.500 -0.050 0.049 
SNAI3         -0.470 -0.368 0.064 -0.067 
TCF4         -0.352 -0.379 0.054 -0.057 
GSC         -5.941 -2.919 0.044 -0.046 
TWIST1         -0.396 -0.493 -0.030 0.029 
FOXC2         -0.151 -0.227 -0.046 0.045 
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